No retraction, correction or concern found when last checked on Oct 18, 2026.

Nanotechnology’s frontier in combatting infectious and inflammatory diseases: prevention and treatment

Yujing Huang, Xiaohan Guo, Yi Wu and 4 more

Signal Transduction and Targeted Therapy · 2024 · Review · CC BY

Abstract

Inflammation-associated diseases encompass a range of infectious diseases and non-infectious inflammatory diseases, which continuously pose one of the most serious threats to human health, attributed to factors such as the emergence of new pathogens, increasing drug resistance, changes in living environments and lifestyles, and the aging population. Despite rapid advancements in mechanistic research and drug development for these diseases, current treatments often have limited efficacy and notable side effects, necessitating the development of more effective and targeted anti-inflammatory therapies. In recent years, the rapid development of nanotechnology has provided crucial technological support for the prevention, treatment, and detection of inflammation-associated diseases. Various types of nanoparticles (NPs) play significant roles, serving as vaccine vehicles to enhance immunogenicity and as drug carriers to improve targeting and bioavailability. NPs can also directly combat pathogens and inflammation. In addition, nanotechnology has facilitated the development of biosensors for pathogen detection and imaging techniques for inflammatory diseases. This review categorizes and characterizes different types of NPs, summarizes their applications in the prevention, treatment, and detection of infectious and inflammatory diseases. It also discusses the challenges associated with clinical translation in this field and explores the latest developments and prospects. In conclusion, nanotechnology opens up new possibilities for the comprehensive management of infectious and inflammatory diseases.

References 804

1.
Inflammatory responses and inflammation-associated diseases in organs · 2017
No notice
2.
Leiba J, et al. Molecular actors of inflammation and their signaling pathways: mechanistic insights from zebrafish. Biology. 2023;12:153.
Not in our library10.3390/biology12020153
3.
Meizlish ML, Franklin RA, Zhou X, Medzhitov R. Tissue homeostasis and inflammation. Annu. Rev. Immunol. 2021;39:557-581.
Not in our library10.1146/annurev-immunol-061020-053734
4.
Sansbury BE, Spite M. Resolution of acute inflammation and the role of resolvins in immunity, thrombosis, and vascular biology. Circ. Res. 2016;119:113-130.
Not in our library10.1161/circresaha.116.307308
5.
Inflammation–Nature's Way to Efficiently Respond to All Types of Challenges: Implications for Understanding and Managing “the Epidemic” of Chronic Diseases · 2018
No notice
6.
Medzhitov R. Origin and physiological roles of inflammation. Nature. 2008;454:428-435.
Not in our library10.1038/nature07201
7.
Neutrophils in chronic inflammatory diseases · 2022
No notice
8.
Brzezicka KA, et al. Suppression of autoimmune rheumatoid arthritis with hybrid nanoparticles that induce B and T cell tolerance to self-antigen. ACS Nano. 2022;16:20206-20221.
Not in our library10.1021/acsnano.2c05643
9.
Yoo D, et al. Anti‐inflammatory glycocalyx‐mimicking nanoparticles for colitis treatment: construction and in vivo evaluation. Angew. Chem. Int. Ed. 2023;62:e202304815.
Not in our library10.1002/anie.202304815
10.
Yuan J, et al. Targeted (otherapies). ACS Nano. 2021;15:16076-16094.
Not in our library10.1021/acsnano.1c04753
11.
Yasamineh S, et al. An overview on nanoparticle-based strategies to fight viral infections with a focus on COVID-19. J. Nanobiotechnol. 2022;20:440.
Not in our library10.1186/s12951-022-01625-0
12.
Huang Y-S, et al. Metal nanoparticles and nanoparticle composites are effective against Haemophilus influenzae, Streptococcus pneumoniae, and multidrug-resistant bacteria. J. Microbiol. Immunol. Infect. 2022;55:708-715.
Not in our library10.1016/j.jmii.2022.05.003
13.
Kaur K, Kumar P, Kush P. Amphotericin B loaded ethyl cellulose nanoparticles with magnified oral bioavailability for safe and effective treatment of fungal infection. Biomed. Pharmacother. 2020;128:110297.
Not in our library10.1016/j.biopha.2020.110297
14.
Zhou Y, et al. Controlled copper in situ growth-amplified lateral flow sensors for sensitive, reliable, and field-deployable infectious disease diagnostics. Biosens. Bioelectron. 2021;171:112753.
Not in our library10.1016/j.bios.2020.112753
15.
González LF, et al. Intranasal delivery of interferon-β-loaded nanoparticles induces control of neuroinflammation in a preclinical model of multiple sclerosis: a promising simple, effective, non-invasive, and low-cost therapy. J. Control Release. 2021;331:443-459.
Not in our library10.1016/j.jconrel.2020.11.019
16.
Zhang L, et al. Nanoenzyme engineered neutrophil-derived exosomes attenuate joint injury in advanced rheumatoid arthritis via regulating inflammatory environment. Bioact. Mater. 2022;18:1-14.
Not in our library10.1016/j.bioactmat.2022.02.017
17.
Lussier F, Staufer O, Platzman I, Spatz JP. Can bottom-up synthetic biology generate advanced drug-delivery systems? Trends Biotechnol. 2021;39:445-459.
Not in our library10.1016/j.tibtech.2020.08.002
18.
Zeng Q, et al. Wound dressing: from nanomaterials to diagnostic dressings and healing evaluations. ACS Nano. 2022;16:1708-1733.
Not in our library10.1021/acsnano.1c08411
19.
Liu T, et al. Nanomaterials and nanomaterials-based drug delivery to promote cutaneous wound healing. Adv. Drug Deliv. Rev. 2023;193:114670.
Not in our library10.1016/j.addr.2022.114670
20.
Geng H, et al. Noble metal nanoparticle biosensors: from fundamental studies toward point-of-care diagnostics. Acc. Chem. Res. 2022;55:593-604.
Not in our library10.1021/acs.accounts.1c00598
21.
Parsamian P, et al. Enhanced nanobubble formation: gold nanoparticle conjugation to Qβ virus-like particles. ACS Nano. 2023;17:7797-7805.
Not in our library10.1021/acsnano.3c00638
22.
Avellan A, et al. Nanoparticle size and coating chemistry control foliar uptake pathways, translocation, and leaf-to-rhizosphere transport in wheat. ACS Nano. 2019;13:5291-5305.
Not in our library10.1021/acsnano.8b09781
23.
Darabdhara G, et al. Ag and Au nanoparticles/reduced graphene oxide composite materials: Synthesis and application in diagnostics and therapeutics. Adv. Colloid Interface Sci. 2019;271:101991.
Not in our library10.1016/j.cis.2019.101991
24.
Shabatina TI, Vernaya OI, Shimanovskiy NL, Melnikov MY. Metal and metal oxides nanoparticles and nanosystems in anticancer and antiviral theragnostic agents. Pharmaceutics. 2023;15:1181.
Not in our library10.3390/pharmaceutics15041181
25.
A comprehensive review on plasmonic-based biosensors used in viral diagnostics · 2021
No notice
26.
Leuschner F, et al. Silencing of CCR2 in myocarditis. Eur. Heart J. 2015;36:1478-1488.
Not in our library10.1093/eurheartj/ehu225
27.
Grippin AJ, et al. Dendritic cell-activating magnetic nanoparticles enable early prediction of antitumor response with magnetic resonance imaging. ACS Nano. 2019;13:13884-13898.
Not in our library10.1021/acsnano.9b05037
28.
Garrido C, et al. Gold nanoparticles to improve HIV drug delivery. Future Med Chem. 2015;7:1097-1107.
Not in our library10.4155/fmc.15.57
29.
Khan T, et al. Plant-based gold nanoparticles; a comprehensive review of the decade-long research on synthesis, mechanistic aspects and diverse applications. Adv. Colloid Interface Sci. 2019;272:102017.
Not in our library10.1016/j.cis.2019.102017
30.
Mechanisms of Silver Nanoparticle Release, Transformation and Toxicity: A Critical Review of Current Knowledge and Recommendations for Future Studies and Applications · 2013
No notice
31.
Nanoparticles: Alternatives Against Drug-Resistant Pathogenic Microbes · 2016
No notice
32.
Porter GC, et al. AgNP/Alginate Nanocomposite hydrogel for antimicrobial and antibiofilm applications. Carbohydr. Polym. 2021;251:117017.
Not in our library10.1016/j.carbpol.2020.117017
33.
Chakravarty M, Vora A. Nanotechnology-based antiviral therapeutics. Drug Deliv. Transl. Res. 2020;11:748-787.
Not in our library10.1007/s13346-020-00818-0
34.
Lara HH, Ixtepan-Turrent L, Garza-Treviño EN, Rodriguez-Padilla C. PVP-coated silver nanoparticles block the transmission of cell-free and cell-associated HIV-1 in human cervical culture. J. Nanobiotechnol. 2010;8:15.
Not in our library10.1186/1477-3155-8-15
35.
Yang Y, et al. Targeted silver nanoparticles for rheumatoid arthritis therapy via macrophage apoptosis and Re-polarization. Biomaterials. 2021;264:120390.
Not in our library10.1016/j.biomaterials.2020.120390
36.
AshaRani PV, Low Kah Mun G, Hande MP, Valiyaveettil S. Cytotoxicity and Genotoxicity of Silver Nanoparticles in Human Cells. ACS Nano. 2008;3:279-290.
Not in our library10.1021/nn800596w
37.
Taheri S, et al. Substrate independent silver nanoparticle based antibacterial coatings. Biomaterials. 2014;35:4601-4609.
Not in our library10.1016/j.biomaterials.2014.02.033
38.
Ye S, et al. Antiviral activity of graphene oxide: how sharp edged structure and charge matter. ACS Appl. Mater. Interfaces. 2015;7:21571-21579.
Not in our library10.1021/acsami.5b06876
39.
Seyed Alian R, et al. Do nanoparticles cause hormesis? Early physiological compensatory response in house crickets to a dietary admixture of GO, Ag, and GOAg composite. Sci. Total Environ. 2021;788:147801.
Not in our library10.1016/j.scitotenv.2021.147801
40.
Xu P-Y, et al. Progress in antiviral fullerene research. Nanomaterials. 2022;12:2547.
Not in our library10.3390/nano12152547
41.
Banerjee I, Douaisi MP, Mondal D, Kane RS. Light-activated nanotube–porphyrin conjugates as effective antiviral agents. Nanotechnology. 2012;23:105101.
Not in our library10.1088/0957-4484/23/10/105101
42.
Sharmeen S, et al. Polyethylene glycol functionalized carbon nanotubes/gelatin-chitosan nanocomposite: An approach for significant drug release. Bioact. Mater. 2018;3:236-244.
Not in our library10.1016/j.bioactmat.2018.03.001
43.
Ramos GS, et al. Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis. Biomed. Pharmacother. 2021;134:111120.
Not in our library10.1016/j.biopha.2020.111120
44.
Khalid A, et al. Multiwalled carbon nanotubes functionalized bacterial cellulose as an efficient healing material for diabetic wounds. Int. J. Biol. Macromol. 2022;203:256-267.
Not in our library10.1016/j.ijbiomac.2022.01.146
45.
Zhang M, Yu P, Mao L. Rational design of surface/interface chemistry for quantitative in vivo monitoring of brain chemistry. Acc. Chem. Res. 2012;45:533-543.
Not in our library10.1021/ar200196h
46.
Panwar N, et al. Nanocarbons for biology and medicine: sensing, imaging, and drug delivery. Chem. Rev. 2019;119:9559-9656.
Not in our library10.1021/acs.chemrev.9b00099
47.
Jariwala D, et al. Carbon nanomaterials for electronics, optoelectronics, photovoltaics, and sensing. Chem. Soc. Rev. 2013;42:2824-2860.
Not in our library10.1039/c2cs35335k
48.
Wang H, et al. Downsized sheath–core conducting fibers for weavable superelastic wires, biosensors, supercapacitors, and strain sensors. Adv. Mater. 2016;28:4998-5007.
Not in our library10.1002/adma.201600405
49.
Bartelmess J, Quinn SJ, Giordani S. Carbon nanomaterials: multi-functional agents for biomedical fluorescence and Raman imaging. Chem. Soc. Rev. 2015;44:4672-4698.
Not in our library10.1039/c4cs00306c
50.
Yang Z, et al. Zero-dimensional carbon nanomaterials for fluorescent sensing and imaging. Chem. Rev. 2023;123:11047-11136.
Not in our library10.1021/acs.chemrev.3c00186
51.
Chen D, Dougherty CA, Zhu K, Hong H. Theranostic applications of carbon nanomaterials in cancer: focus on imaging and cargo delivery. J. Control Release. 2015;210:230-245.
Not in our library10.1016/j.jconrel.2015.04.021
52.
Kumar S, et al. Carbon nanotubes: a novel material for multifaceted applications in human healthcare. Chem. Soc. Rev. 2017;46:158-196.
Not in our library10.1039/c6cs00517a
53.
Alagarsamy KN, et al. Carbon nanomaterials for cardiovascular theranostics: promises and challenges. Bioact. Mater. 2021;6:2261-2280.
Not in our library10.1016/j.bioactmat.2020.12.030
54.
Hou X, Zaks T, Langer R, Dong Y. Lipid nanoparticles for mRNA delivery. Nature reviews. Materials. 2021;6:1078-1094.
Not in our library10.1038/s41578-021-00358-0
55.
Wang C, Zhang Y, Dong Y. Lipid nanoparticle–mRNA formulations for therapeutic applications. Acc. Chem. Res. 2021;54:4283-4293.
Not in our library10.1021/acs.accounts.1c00550
56.
Böttger R, et al. Lipid-based nanoparticle technologies for liver targeting. Adv. Drug Deliv. Rev. 2020;154-155:79-101.
Not in our library10.1016/j.addr.2020.06.017
57.
Puri A, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit. Rev. Ther. Drug Carr. Syst. 2009;26:523-580.
Not in our library10.1615/critrevtherdrugcarriersyst.v26.i6.10
58.
Alameh M-G, et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity. 2021;54:2877-2892.e2877.
Not in our library10.1016/j.immuni.2021.11.001
59.
Tenchov R, Bird R, Curtze AE, Zhou Q. Lipid nanoparticles—from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15:16982-17015.
Not in our library10.1021/acsnano.1c04996
60.
Deng Y-Q, et al. Lipid nanoparticle-encapsulated mRNA antibody provides long-term protection against SARS-CoV-2 in mice and hamsters. Cell Res. 2022;32:375-382.
Not in our library10.1038/s41422-022-00630-0
61.
Swingle KL, Hamilton AG, Mitchell MJ. Lipid nanoparticle-mediated delivery of mRNA therapeutics and vaccines. Trends Mol. Med. 2021;27:616-617.
Not in our library10.1016/j.molmed.2021.03.003
62.
Li T, Cipolla D, Rades T, Boyd BJ. Drug nanocrystallisation within liposomes. J. Control Release. 2018;288:96-110.
Not in our library10.1016/j.jconrel.2018.09.001
63.
Yang T, et al. Liposome formulation of paclitaxel with enhanced solubility and stability. Drug Deliv. 2008;14:301-308.
Not in our library10.1080/10717540601098799
64.
Mehta RT. Liposome encapsulation of clofazimine reduces toxicity in vitro and in vivo and improves therapeutic efficacy in the beige mouse model of disseminated Mycobacterium avium-M. intracellulare complex infection. Antimicrob. Agents Chemother. 1996;40:1893-1902.
Not in our library10.1128/aac.40.8.1893
65.
A Review of Liposomes as a Drug Delivery System: Current Status of Approved Products, Regulatory Environments, and Future Perspectives · 2022
No notice
66.
Bhaskaran NA, et al. Orally delivered solid lipid nanoparticles of irinotecan coupled with chitosan surface modification to treat colon cancer: Preparation, in-vitro and in-vivo evaluations. Int. J. Biol. Macromol. 2022;211:301-315.
Not in our library10.1016/j.ijbiomac.2022.05.060
67.
Buzyurova DN, et al. Surface modification of pralidoxime chloride-loaded solid lipid nanoparticles for enhanced brain reactivation of organophosphorus-inhibited AChE: pharmacokinetics in rat. Toxicology. 2020;444:152578.
Not in our library10.1016/j.tox.2020.152578
68.
Nabi B, Rehman S, Baboota S, Ali J. Insights on oral drug delivery of lipid nanocarriers: a win-win solution for augmenting bioavailability of antiretroviral drugs. AAPS PharmSciTech. 2019;20:60.
Not in our library10.1208/s12249-018-1284-9
69.
Xu Y, et al. Surface modification of lipid-based nanoparticles. ACS Nano. 2022;16:7168-7196.
Not in our library10.1021/acsnano.2c02347
70.
Freyn AW, et al. A multi-targeting, nucleoside-modified mRNA influenza virus vaccine provides broad protection in mice. Mol. Ther. 2020;28:1569-1584.
Not in our library10.1016/j.ymthe.2020.04.018
71.
Verma AK, Perlman S. Lipid nanoparticle-mRNA: another step in the fight against COVID-19. Cell Res. 2022;32:421-422.
Not in our library10.1038/s41422-022-00647-5
72.
Ball R, Bajaj P, Whitehead K. Achieving long-term stability of lipid nanoparticles: examining the effect of pH, temperature, and lyophilization. Int. J. Nanomed. 2016;12:305-315.
Not in our library10.2147/ijn.s123062
73.
Li Y, Ye Z, Yang H, Xu Q. Tailoring combinatorial lipid nanoparticles for intracellular delivery of nucleic acids, proteins, and drugs. Acta Pharm. Sin. B. 2022;12:2624-2639.
Not in our library10.1016/j.apsb.2022.04.013
74.
Qin Y, et al. Evaluation of a DoE based approach for comprehensive modelling of the effect of lipid nanoparticle composition on nucleic acid delivery. Biomaterials. 2023;299:122158.
Not in our library10.1016/j.biomaterials.2023.122158
75.
Cui L, et al. Mechanistic studies of an automated lipid nanoparticle reveal critical pharmaceutical properties associated with enhanced mRNA functional delivery in vitro and in vivo. Small. 2021;18:e2105832.
Not in our library10.1002/smll.202105832
76.
Wang Z, et al. Development and applications of mRNA treatment based on lipid nanoparticles. Biotechnol. Adv. 2023;65:108130.
Not in our library10.1016/j.biotechadv.2023.108130
77.
Li Z, et al. Enzyme-catalyzed one-step synthesis of ionizable cationic lipids for lipid nanoparticle-based mRNA COVID-19 vaccines. ACS Nano. 2022;16:18936-18950.
Not in our library10.1021/acsnano.2c07822
78.
Samaridou E, Heyes J, Lutwyche P. Lipid nanoparticles for nucleic acid delivery: current perspectives. Adv. Drug Deliv. Rev. 2020;154-155:37-63.
Not in our library10.1016/j.addr.2020.06.002
79.
Barriga HMG, et al. Coupling lipid nanoparticle structure and automated single‐particle composition analysis to design phospholipase‐responsive nanocarriers. Adv. Mater. 2022;34:e2200839.
Not in our library10.1002/adma.202200839
80.
Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA · 2020
Corrected
81.
Eygeris Y, Gupta M, Kim J, Sahay G. Chemistry of lipid nanoparticles for RNA delivery. Acc. Chem. Res. 2021;55:2-12.
Not in our library10.1021/acs.accounts.1c00544
82.
Paoletti, A. et al. Liposomal antagomiR‐155‐5p restores anti‐inflammatory macrophages and improves arthritis in preclinical models of rheumatoid arthritis. Arthritis Rheumatol. 10.1002/art.42665 (2023).
Not in our library10.1002/art.42665
83.
Bevilacqua Rolfsen Ferreira da Silva G, et al. Comparative effectiveness of preventive treatment with dimethyl fumarate-loaded solid lipid nanoparticles and oral dimethyl fumarate in a mouse model of multiple sclerosis. J. Autoimmun. 2022;132:102893.
Not in our library10.1016/j.jaut.2022.102893
84.
Wang S, et al. Sialic acid-conjugate modified doxorubicin nanoplatform for treating neutrophil-related inflammation. J. Control Release. 2021;337:612-627.
Not in our library10.1016/j.jconrel.2021.07.044
85.
Zhou A, et al. Bioengineered neutrophil extinguisher targets cascade immune pathways of macrophages for alleviating cytokine storm in pneumonia. ACS Nano. 2023;17:16461-16477.
Not in our library10.1021/acsnano.3c00227
86.
Satta S, et al. An engineered nano-liposome-human ACE2 decoy neutralizes SARS-CoV-2 Spike protein-induced inflammation in both murine and human macrophages. Theranostics. 2022;12:2639-2657.
Not in our library10.7150/thno.66831
87.
Kolyvushko O, et al. Differentially-charged liposomes interact with alphaherpesviruses and interfere with virus entry. Pathogens. 2020;9:359.
Not in our library10.3390/pathogens9050359
88.
Kauffman KJ, et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 2015;15:7300-7306.
Not in our library10.1021/acs.nanolett.5b02497
89.
Oberli MA, et al. Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy. Nano Lett. 2016;17:1326-1335.
Not in our library10.1021/acs.nanolett.6b03329
90.
Liang F, et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol. Ther. 2017;25:2635-2647.
Not in our library10.1016/j.ymthe.2017.08.006
91.
Halperin SA, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022;399:237-248.
Not in our library10.1016/s0140-6736(21)02753-7
92.
Verbeke R, Hogan MJ, Loré K, Pardi N. Innate immune mechanisms of mRNA vaccines. Immunity. 2022;55:1993-2005.
Not in our library10.1016/j.immuni.2022.10.014
93.
Li B, et al. Combinatorial design of nanoparticles for pulmonary mRNA delivery and genome editing. Nat. Biotechnol. 2023;41:1410-1415.
Not in our library10.1038/s41587-023-01679-x
94.
Cheng CJ, Tietjen GT, Saucier-Sawyer JK, Saltzman WM. A holistic approach to targeting disease with polymeric nanoparticles. Nat. Rev. Drug Discov. 2015;14:239-247.
Not in our library10.1038/nrd4503
95.
Liu B, et al. In situ formation of polymeric nanoassemblies using an efficient reversible click reaction. Angew. Chem. Int. Ed. 2020;59:15135-15140.
Not in our library10.1002/anie.202004017
96.
Liu Q, et al. Use of polymeric nanoparticle platform targeting the liver to induce treg-mediated antigen-specific immune tolerance in a pulmonary allergen sensitization model. ACS Nano. 2019;13:4778-4794.
Not in our library10.1021/acsnano.9b01444
97.
Wu H, et al. Brain targeting, antioxidant polymeric nanoparticles for stroke drug delivery and therapy. Small. 2022;18:e2107126.
Not in our library10.1002/smll.202107126
98.
Liao R, Pon J, Chungyoun M, Nance E. Enzymatic protection and biocompatibility screening of enzyme-loaded polymeric nanoparticles for neurotherapeutic applications. Biomaterials. 2020;257:120238.
Not in our library10.1016/j.biomaterials.2020.120238
99.
Cordeiro AS, et al. Nanovaccine delivery approaches and advanced delivery systems for the prevention of viral infections: from development to clinical application. Pharmaceutics. 2021;13:2091.
Not in our library10.3390/pharmaceutics13122091
100.
Biodegradable Polymeric Nanoparticles-Based Vaccine Adjuvants for Lymph Nodes Targeting · 2016
Not checked
101.
Peviani M, et al. Biodegradable polymeric nanoparticles administered in the cerebrospinal fluid: Brain biodistribution, preferential internalization in microglia and implications for cell-selective drug release. Biomaterials. 2019;209:25-40.
Not in our library10.1016/j.biomaterials.2019.04.012
102.
Wibowo D, et al. Polymeric nanoparticle vaccines to combat emerging and pandemic threats. Biomaterials. 2021;268:120597.
Not in our library10.1016/j.biomaterials.2020.120597
103.
Yin Q, et al. A TLR7-nanoparticle adjuvant promotes a broad immune response against heterologous strains of influenza and SARS-CoV-2. Nat. Mater. 2023;22:380-390.
Not in our library10.1038/s41563-022-01464-2
104.
El-Sissi AF, et al. Chitosan and chitosan nanoparticles as adjuvant in local Rift Valley Fever inactivated vaccine. 3 Biotech. 2020;10:88.
Not in our library10.1007/s13205-020-2076-y
105.
Thomas C, Rawat A, Hope-Weeks L, Ahsan F, Aerosolized PLA. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol. Pharm. 2011;8:405-415.
Not in our library10.1021/mp100255c
106.
Protein nanoparticles in drug delivery: animal protein, plant proteins and protein cages, albumin nanoparticles · 2021
No notice
107.
Habibi N, Mauser A, Ko Y, Lahann J. Protein nanoparticles: uniting the power of proteins with engineering design approaches. Adv. Sci. 2022;9:e2104012.
Not in our library10.1002/advs.202104012
108.
Cai R, Chen C. The crown and the scepter: roles of the protein corona in nanomedicine. Adv. Mater. 2018;31:e1805740.
Not in our library10.1002/adma.201805740
109.
Stupka I. & Heddle, J. G. Artificial protein cages—inspiration, construction, and observation. Curr. Opin. Struct. Biol. 2020;64:66-73.
Not in our library10.1016/j.sbi.2020.05.014
110.
Vázquez E, Villaverde A. Engineering building blocks for self-assembling protein nanoparticles. Microb. Cell Factories. 2010;9:101.
Not in our library10.1186/1475-2859-9-101
111.
Theil ECFerritin. The protein nanocage and iron biomineral in health and in disease. Inorg. Chem. 2013;52:12223-12233.
Not in our library10.1021/ic400484n
112.
Waters ER, Vierling E. Plant small heat shock proteins—evolutionary and functional diversity. N. Phytol. 2020;227:24-37.
Not in our library10.1111/nph.16536
113.
Protein Polymer-Based Nanoparticles: Fabrication and Medical Applications · 2018
No notice
114.
de Pinho Favaro MT, et al. Protein nanoparticles are nontoxic, tuneable cell stressors. Nanomedicine. 2018;13:255-268.
Not in our library10.2217/nnm-2017-0294
115.
Mechanistic understanding of in vivo protein corona formation on polymeric nanoparticles and impact on pharmacokinetics · 2017
No notice
116.
Nayak D, et al. Stavudine loaded gelatin liposomes for HIV therapy: preparation, characterization and in vitro cytotoxic evaluation. Mater. Sci. Eng. C. 2017;73:406-416.
Not in our library10.1016/j.msec.2016.12.073
117.
Kang MG, et al. Nanogels derived from fish gelatin: application to drug delivery system. Mar. Drugs. 2019;17:246.
Not in our library10.3390/md17040246
118.
Salvati A, et al. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat. Nanotechnol. 2013;8:137-143.
Not in our library10.1038/nnano.2012.237
119.
Doan VS, Chun S, Feng J, Shin S. Confinement-dependent diffusiophoretic transport of nanoparticles in collagen hydrogels. Nano Lett. 2021;21:7625-7630.
Not in our library10.1021/acs.nanolett.1c02251
120.
McColman S, et al. Serum proteins on nanoparticles: early stages of the “protein corona”. Nanoscale. 2021;13:20550-20563.
Not in our library10.1039/d1nr06137b
121.
Müller J, et al. Denaturation via surfactants changes composition of protein corona. Biomacromolecules. 2018;19:2657-2664.
Not in our library10.1021/acs.biomac.8b00278
122.
Tobola F, Wiltschi B. One, two, many: strategies to alter the number of carbohydrate binding sites of lectins. Biotechnol. Adv. 2022;60:108020.
Not in our library10.1016/j.biotechadv.2022.108020
123.
Dan X, Liu W, Ng TB. Development and applications of lectins as biological tools in biomedical research. Med. Res Rev. 2015;36:221-247.
Not in our library10.1002/med.21363
124.
Virus-like particle vaccinology, from bench to bedside · 2022
No notice
125.
Interaction of Viral Capsid-Derived Virus-Like Particles (VLPs) with the Innate Immune System · 2018
No notice
126.
Mohsen MO, et al. A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2. Allergy. 2021;77:243-257.
Not in our library10.1111/all.15080
127.
Krug PW, et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci. Adv. 2023;9:eadg6076.
Not in our library10.1126/sciadv.adg6076
128.
Kong J, et al. Rationally designed peptidyl virus‐like particles enable targeted delivery of genetic cargo. Angew. Chem. Int. Ed. 2018;57:14032-14036.
Not in our library10.1002/anie.201805868
129.
Suffian IFBM, Al-Jamal KT. Bioengineering of virus-like particles as dynamic nanocarriers for in vivo delivery and targeting to solid tumours. Adv. Drug Deliv. Rev. 2022;180:114030.
Not in our library10.1016/j.addr.2021.114030
130.
Fiebiger E, et al. Cytokines regulate proteolysis in major histocompatibility complex class II-dependent antigen presentation by dendritic cells. J. Exp. Med. 2001;193:881-892.
Not in our library10.1084/jem.193.8.881
131.
Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers · 2021
No notice
132.
Krizkova S, et al. Nanotechnologies in protein microarrays. Nanomedicine. 2015;10:2743-2755.
Not in our library10.2217/nnm.15.81
133.
Tumor-associated exosomes promote lung cancer metastasis through multiple mechanisms · 2021
No notice
134.
Peng Y, et al. Exosome and virus infection. Front. Immunol. 2023;14:1154217.
Not in our library10.3389/fimmu.2023.1154217
135.
Therapeutic potential and mechanisms of mesenchymal stem cell-derived exosomes as bioactive materials in tendon–bone healing · 2023
No notice
136.
Pegtel DM, Gould SJ. Exosomes. Annu. Rev. Biochem. 2019;88:487-514.
Not in our library10.1146/annurev-biochem-013118-111902
137.
Gunassekaran GR, Poongkavithai Vadevoo SM, Baek M-C, Lee B. M1 macrophage exosomes engineered to foster M1 polarization and target the IL-4 receptor inhibit tumor growth by reprogramming tumor-associated macrophages into M1-like macrophages. Biomaterials. 2021;278:121137.
Not in our library10.1016/j.biomaterials.2021.121137
138.
Tao S-C, et al. Exosomes derived from miR-140-5p-overexpressing human synovial mesenchymal stem cells enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rat model. Theranostics. 2017;7:180-195.
Not in our library10.7150/thno.17133
139.
Nanomaterials for cancer therapy: current progress and perspectives · 2021
No notice
140.
Xiao, Y. et al. Mesenchymal stem cell-derived exosomes: versatile nanomaterials for skin wound treatment. Nano Res. 10.1007/s12274-023-6080-5 (2023).
Not in our library
141.
Perocheau D, et al. Clinical applications for exosomes: are we there yet? Br. J. Pharmacol. 2021;178:2375-2392.
Not in our library10.1111/bph.15432
142.
Exosome-mediated mRNA delivery in vivo is safe and can be used to induce SARS-CoV-2 immunity · 2021
No notice
143.
Wang Z, et al. Exosomes decorated with a recombinant SARS-CoV-2 receptor-binding domain as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 2022;6:791-805.
Not in our library10.1038/s41551-022-00902-5
144.
Pei W, et al. Exosome membrane-modified M2 macrophages targeted nanomedicine: treatment for allergic asthma. J. Control Release. 2021;338:253-267.
Not in our library10.1016/j.jconrel.2021.08.024
145.
He C, Zheng S, Luo Y, Wang B. Exosome theranostics: biology and translational medicine. Theranostics. 2018;8:237-255.
Not in our library10.7150/thno.21945
146.
Xu Y-X, et al. Exosomal ncRNAs: Novel therapeutic target and biomarker for diabetic complications. Pharmacol. Res. 2022;178:106135.
Not in our library10.1016/j.phrs.2022.106135
147.
Zhu X, et al. Alone and combined toxicity of ZnO nanoparticles and graphene quantum dots on microalgae Gymnodinium. Environ. Sci. Pollut. Res. 2022;29:47310-47322.
Not in our library10.1007/s11356-022-19267-y
148.
Zhou Y, et al. PLLA microcapsules combined with silver nanoparticles and chlorhexidine acetate showing improved antibacterial effect. Mater. Sci. Eng. C. 2017;78:349-353.
Not in our library10.1016/j.msec.2017.04.100
149.
Xu Z, Shi L, Yang M, Zhu L. Preparation and biomedical applications of silk fibroin-nanoparticles composites with enhanced properties—a review. Mater. Sci. Eng. C. 2019;95:302-311.
Not in our library10.1016/j.msec.2018.11.010
150.
Jiang D, et al. Nanozyme: new horizons for responsive biomedical applications. Chem. Soc. Rev. 2019;48:3683-3704.
Not in our library10.1039/c8cs00718g
151.
Sharma G, et al. Advances in nanozymes as a paradigm for viral diagnostics and therapy. Pharmacol. Rev. 2023;75:739-757.
Not in our library10.1124/pharmrev.122.000719
152.
Wang J, et al. Utilizing nanozymes for combating COVID-19: advancements in diagnostics, treatments, and preventative measures. J. Nanobiotechnol. 2023;21:200.
Not in our library10.1186/s12951-023-01945-9
153.
Hou J, Xianyu Y. Tailoring the surface and composition of nanozymes for enhanced bacterial binding and antibacterial activity. Small. 2023;19:e2302640.
Not in our library10.1002/smll.202302640
154.
Kumar V, et al. Recent technological advances in mechanism, toxicity, and food perspectives of enzyme-mediated aflatoxin degradation. Crit. Rev. Food Sci. Nutr. 2021;62:5395-5412.
Not in our library10.1080/10408398.2021.2010647
155.
Songca SP. Applications of nanozymology in the detection and identification of viral, bacterial and fungal pathogens. Int. J. Mol. Sci. 2022;23:4638.
Not in our library10.3390/ijms23094638
156.
Nanomaterials alleviating redox stress in neurological diseases: mechanisms and applications · 2022
Not checked
157.
Salvador-Morales C, Grodzinski P. Nanotechnology Tools Enabling Biological Discovery. ACS Nano. 2022;16:5062-5084.
Not in our library10.1021/acsnano.1c10635
158.
Yuan Y, et al. Histidine modulates amyloid-like assembly of peptide nanomaterials and confers enzyme-like activity. Nat. Commun. 2023;14:5808.
Not in our library10.1038/s41467-023-41591-1
159.
Ma M, et al. Self-protecting biomimetic nanozyme for selective and synergistic clearance of peripheral amyloid-β in an Alzheimer’s disease model. J. Am. Chem. Soc. 2020;142:21702-21711.
Not in our library10.1021/jacs.0c08395
160.
Ji W, et al. Self‐catalytic small interfering RNA nanocarriers for synergistic treatment of neurodegenerative diseases. Adv. Mater. 2021;34:e2105711.
Not in our library10.1002/adma.202105711
161.
Wang, Z. et al. A thrombin‐activated peptide‐templated nanozyme for remedying ischemic stroke via thrombolytic and neuroprotective actions. Adv. Mater. 10.1002/adma.202210144 (2023).
Not in our library10.1002/adma.202210144
162.
Liu Y, et al. Multifunctional Janus nanoplatform for efficiently synergistic theranostics of rheumatoid arthritis. ACS Nano. 2023;17:8167-8182.
Not in our library10.1021/acsnano.2c11777
163.
Pudineh Moarref M, Alimolaei M, Emami T, Koohi MK. Development and evaluation of cell membrane-based biomimetic nanoparticles loaded by Clostridium perfringens epsilon toxin: a novel vaccine delivery platform for Clostridial-associated diseases. Nanotoxicology. 2023;17:420-431.
Not in our library10.1080/17435390.2023.2252899
164.
Jeong Y, et al. Stimuli-responsive adaptive nanotoxin to directly penetrate the cellular membrane by molecular folding and unfolding. J. Am. Chem. Soc. 2022;144:5503-5516.
Not in our library10.1021/jacs.2c00084
165.
Wu P, Yan X-P. Doped quantum dots for chemo/biosensing and bioimaging. Chem. Soc. Rev. 2013;42:5489-5521.
Not in our library10.1039/c3cs60017c
166.
Wang Z-G, Liu S-L, Pang D-W. Quantum dots: a promising fluorescent label for probing virus trafficking. Acc. Chem. Res. 2021;54:2991-3002.
Not in our library10.1021/acs.accounts.1c00276
167.
Liu S-L, Wang Z-G, Zhang Z-L, Pang D-W. Tracking single viruses infecting their host cells using quantum dots. Chem. Soc. Rev. 2016;45:1211-1224.
Not in our library10.1039/c5cs00657k
168.
Ashrafizadeh M, et al. Carbon dots as versatile nanoarchitectures for the treatment of neurological disorders and their theranostic applications: A review. Adv. Colloid Interface Sci. 2020;278:102123.
Not in our library10.1016/j.cis.2020.102123
169.
Gopalan D, Pandey A, Udupa N, Mutalik S. Receptor specific, stimuli responsive and subcellular targeted approaches for effective therapy of Alzheimer: Role of surface engineered nanocarriers. J. Control Release. 2020;319:183-200.
Not in our library10.1016/j.jconrel.2019.12.034
170.
Ma Z, et al. Near‐infrared IIb fluorescence imaging of vascular regeneration with dynamic tissue perfusion measurement and high spatial resolution. Adv. Funct. Mater. 2018;28:1803417.
Not in our library10.1002/adfm.201803417
171.
Wu G, et al. Enhanced proliferation of visualizable mesenchymal stem cell–platelet hybrid cell for versatile intracerebral hemorrhage treatment. ACS Nano. 2023;17:7352-7365.
Not in our library10.1021/acsnano.2c11329
172.
Kirtane AR, et al. Nanotechnology approaches for global infectious diseases. Nat. Nanotechnol. 2021;16:369-384.
Not in our library10.1038/s41565-021-00866-8
173.
Zhong NS, et al. Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People’s Republic of China, in February, 2003. Lancet. 2003;362:1353-1358.
Not in our library10.1016/s0140-6736(03)14630-2
174.
Gerberding JL. Influenza in 2009. Jama. 2009;302:1907-1908,.
Not in our library10.1001/jama.2009.1617
175.
Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet. 2015;386:995-1007.
Not in our library10.1016/s0140-6736(15)60454-8
176.
Malvy D, et al. Ebola virus disease. Lancet. 2019;393:936-948.
Not in our library10.1016/s0140-6736(18)33132-5
177.
Pacheco O, et al. Zika virus disease in colombia—preliminary report. N. Engl. J. Med. 2020;383:e44.
Not in our library10.1056/nejmoa1604037
178.
Hu B, Guo H, Zhou P, Shi Z-L. Characteristics of SARS-CoV-2 and COVID-19. Nat. Rev. Microbiol. 2020;19:141-154.
Not in our library10.1038/s41579-020-00459-7
179.
Baker RE, et al. Infectious disease in an era of global change. Nat. Rev. Microbiol. 2021;20:193-205.
Not in our library10.1038/s41579-021-00639-z
180.
Excler J-L, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat. Med. 2021;27:591-600.
Not in our library10.1038/s41591-021-01301-0
181.
Graham BS, Sullivan NJ. Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. Nat. Immunol. 2017;19:20-28.
Not in our library10.1038/s41590-017-0007-9
182.
Gu W, Miller S, Chiu CY. Clinical metagenomic next-generation sequencing for pathogen detection. Annu. Rev. Pathol. 2019;14:319-338.
Not in our library10.1146/annurev-pathmechdis-012418-012751
183.
Goharshadi EK, Goharshadi K, Moghayedi M. The use of nanotechnology in the fight against viruses: a critical review. Coord. Chem. Rev. 2022;464:214559.
Not in our library10.1016/j.ccr.2022.214559
184.
Ren H, et al. Adjuvant physiochemistry and advanced nanotechnology for vaccine development. Chem. Soc. Rev. 2023;52:5172-5254.
Not in our library10.1039/d2cs00848c
185.
Akinc A, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 2019;14:1084-1087.
Not in our library10.1038/s41565-019-0591-y
186.
Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nat. Biotechnol. 2015;33:941-951.
Not in our library10.1038/nbt.3330
187.
Mitchell MJ, et al. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 2020;20:101-124.
Not in our library10.1038/s41573-020-0090-8
188.
Singh L, et al. The role of nanotechnology in the treatment of viral infections. Ther. Adv. Infect. Dis. 2017;4:105-131.
Not in our library10.1177/2049936117713593
189.
Feng C, et al. Emerging vaccine nanotechnology: from defense against infection to sniping cancer. Acta Pharm. Sin. B. 2022;12:2206-2223.
Not in our library10.1016/j.apsb.2021.12.021
190.
Xu Z, et al. In vivo assembly of nanoparticles achieved through synergy of structure‐based protein engineering and synthetic DNA generates enhanced adaptive immunity. Adv. Sci. 2020;7:1902802.
Not in our library10.1002/advs.201902802
191.
Park KS, Sun X, Aikins ME, Moon JJ. Non-viral COVID-19 vaccine delivery systems. Adv. Drug Deliv. Rev. 2021;169:137-151.
Not in our library10.1016/j.addr.2020.12.008
192.
Islam MA, et al. Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice. Biomaterials. 2021;266:120431.
Not in our library10.1016/j.biomaterials.2020.120431
193.
Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 2018;17:261-279.
Not in our library10.1038/nrd.2017.243
194.
Linkage between endosomal escape of LNP-mRNA and loading into EVs for transport to other cells · 2019
No notice
195.
Zhang Y-Q, et al. Ionizable drug delivery systems for efficient and selective gene therapy. Mil. Med. Res. 2023;10:9.
Not in our library10.1186/s40779-023-00445-z
196.
Khurana A, et al. Role of nanotechnology behind the success of mRNA vaccines for COVID-19. Nano Today. 2021;38:101142.
Not in our library10.1016/j.nantod.2021.101142
197.
Zagorski K, et al. Modular nanoarray vaccine for SARS-CoV-2. Nanomedicine. 2022;46:102604.
Not in our library10.1016/j.nano.2022.102604
198.
Hoffmann MAG, et al. ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Cell. 2023;186:2380-2391.e2389.
Not in our library10.1016/j.cell.2023.04.024
199.
Atmar RL, et al. Homologous and heterologous Covid-19 booster vaccinations. N. Engl. J. Med. 2022;386:1046-1057.
Not in our library10.1056/nejmoa2116414
200.
Jain S, Venkataraman A, Wechsler ME, Peppas NA. Messenger RNA-based vaccines: Past, present, and future directions in the context of the COVID-19 pandemic. Adv. Drug Deliv. Rev. 2021;179:114000.
Not in our library10.1016/j.addr.2021.114000
201.
Modified mRNA/lipid nanoparticle-based vaccines expressing respiratory syncytial virus F protein variants are immunogenic and protective in rodent models of RSV infection · 2020
No notice
202.
Valentin A, et al. Comparative immunogenicity of an mRNA/LNP and a DNA vaccine targeting HIV gag conserved elements in macaques. Front. Immunol. 2022;13:945706.
Not in our library10.3389/fimmu.2022.945706
203.
Peng L, et al. Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Rep. 2022;40:111160.
Not in our library10.1016/j.celrep.2022.111160
204.
Kanekiyo M, et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature. 2013;499:102-106.
Not in our library10.1038/nature12202
205.
Frietze KM, Peabody DS, Chackerian B. Engineering virus-like particles as vaccine platforms. Curr. Opin. Virol. 2016;18:44-49.
Not in our library10.1016/j.coviro.2016.03.001
206.
SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice · 2021
No notice
207.
Dunkle LM, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N. Engl. J. Med. 2022;386:531-543.
Not in our library10.1056/nejmoa2116185
208.
He C, et al. A self-assembled trimeric protein vaccine induces protective immunity against Omicron variant. Nat. Commun. 2022;13:5459.
Not in our library10.1038/s41467-022-33209-9
209.
Computational Design of a Novel VLP-Based Vaccine for Hepatitis B Virus · 2020
Not checked
210.
Bei L, et al. Immunogenicity correlation in cynomolgus monkeys between Luminex‐based total IgG immunoassay and pseudovirion‐based neutralization assay for a 14‐valent recombinant human papillomavirus vaccine. J. Med. Virol. 2022;94:3946-3955.
Not in our library10.1002/jmv.27763
211.
Hui X, et al. PSMD12-mediated M1 ubiquitination of influenza A virus at K102 regulates viral replication. J. Virol. 2022;96:e0078622.
Not in our library10.1128/jvi.00786-22
212.
Shinde V, et al. Comparison of the safety and immunogenicity of a novel Matrix-M-adjuvanted nanoparticle influenza vaccine with a quadrivalent seasonal influenza vaccine in older adults: a phase 3 randomised controlled trial. Lancet Infect. Dis. 2022;22:73-84.
Not in our library10.1016/s1473-3099(21)00192-4
213.
McComb RC, et al. Presentation of peptides from Bacillus anthracis protective antigen on Tobacco Mosaic Virus as an epitope targeted anthrax vaccine. Vaccine. 2015;33:6745-6751.
Not in our library10.1016/j.vaccine.2015.10.075
214.
August A, et al. A Phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine. 2017;35:3749-3759.
Not in our library10.1016/j.vaccine.2017.05.045
215.
Kang Y-F, et al. Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates. ACS Nano. 2021;15:2738-2752.
Not in our library10.1021/acsnano.0c08379
216.
Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial · 2022
No notice
217.
Kim MY, et al. Molecular engineering and plant expression of an immunoglobulin heavy chain scaffold for delivery of a dengue vaccine candidate. Plant Biotechnol. J. 2017;15:1590-1601.
Not in our library10.1111/pbi.12741
218.
Wen Y, Waltman A, Han H, Collier JH. Switching the immunogenicity of peptide assemblies using surface properties. ACS Nano. 2016;10:9274-9286.
Not in our library10.1021/acsnano.6b03409
219.
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2 · 2020
No notice
220.
Arunachalam PS, et al. Adjuvanting a subunit COVID-19 vaccine to induce protective immunity. Nature. 2021;594:253-258.
Not in our library10.1038/s41586-021-03530-2
221.
Brouwer PJM, et al. Lassa virus glycoprotein nanoparticles elicit neutralizing antibody responses and protection. Cell Host Microbe. 2022;30:1759-1772.e1712.
Not in our library10.1016/j.chom.2022.10.018
222.
Enhancing and shaping the immunogenicity of native-like HIV-1 envelope trimers with a two-component protein nanoparticle · 2019
No notice
223.
Sliepen K, et al. Induction of cross-neutralizing antibodies by a permuted hepatitis C virus glycoprotein nanoparticle vaccine candidate. Nat. Commun. 2022;13:7271.
Not in our library10.1038/s41467-022-34961-8
224.
Lacasta A, et al. Design and immunological evaluation of two-component protein nanoparticle vaccines for East Coast fever. Front. Immunol. 2023;13:1015840.
Not in our library10.3389/fimmu.2022.1015840
225.
Exosome-Based Vaccines: History, Current State, and Clinical Trials · 2021
No notice
226.
Popowski KD, et al. Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter. 2022;5:2960-2974.
Not in our library10.1016/j.matt.2022.06.012
227.
Zhang Q, et al. Intraduodenal delivery of exosome-loaded SARS-CoV-2 RBD mRNA induces a neutralizing antibody response in mice. Vaccines. 2023;11:673.
Not in our library10.3390/vaccines11030673
228.
Cacciottolo M, et al. Exosome-based multivalent vaccine: achieving potent immunization, broadened reactivity, and strong T-cell responses with nanograms of proteins. Microbiol. Spectr. 2023;11:e0050323.
Not in our library10.1128/spectrum.00503-23
229.
Wang R, et al. Novel exosome-targeted T-cell-based vaccine counteracts T-cell anergy and converts CTL exhaustion in chronic infection via CD40L signaling through the mTORC1 pathway. Cell. Mol. Immunol. 2016;14:529-545.
Not in our library10.1038/cmi.2016.23
230.
Jesus S, Soares E, Cruz MT, Borges O. Exosomes as adjuvants for the recombinant hepatitis B antigen: First report. Eur. J. Pharm. Biopharm. 2018;133:1-11.
Not in our library10.1016/j.ejpb.2018.09.029
231.
Exosomal MicroRNAs Derived From Umbilical Mesenchymal Stem Cells Inhibit Hepatitis C Virus Infection · 2016
Not checked
232.
Bioengineering commensal bacteria‐derived outer membrane vesicles for delivery of biologics to the gastrointestinal and respiratory tract · 2019
No notice
233.
Wang J, et al. Exosome-mediated delivery of inducible miR-423-5p enhances resistance of MRC-5 cells to rabies virus infection. Int. J. Mol. Sci. 2019;20:1537.
Not in our library10.3390/ijms20071537
234.
Ma M, et al. Quasi-amorphous and hierarchical Fe2O3 supraparticles: active T1-weighted magnetic resonance imaging in vivo and renal clearance. ACS Nano. 2020;14:4036-4044.
Not in our library10.1021/acsnano.9b08570
235.
Kulkarni JA, et al. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc. Chem. Res. 2019;52:2435-2444.
Not in our library10.1021/acs.accounts.9b00368
236.
Zeng L, et al. Broad-spectrum CRISPR-mediated inhibition of SARS-CoV-2 variants and endemic coronaviruses in vitro. Nat. Commun. 2022;13:2766.
Not in our library10.1038/s41467-022-30546-7
237.
Verma A, et al. Surface-structure-regulated cell-membrane penetration by monolayer-protected nanoparticles. Nat. Mater. 2008;7:588-595.
Not in our library10.1038/nmat2202
238.
Xin X, et al. Rod‐shaped active drug particles enable efficient and safe gene delivery. Adv. Sci. 2017;4:1700324.
Not in our library10.1002/advs.201700324
239.
Cullis J, et al. Macropinocytosis of Nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunol. Res. 2017;5:182-190.
Not in our library10.1158/2326-6066.cir-16-0125
240.
Donahue ND, Acar H, Wilhelm S. Concepts of nanoparticle cellular uptake, intracellular trafficking, and kinetics in nanomedicine. Adv. Drug Deliv. Rev. 2019;143:68-96.
Not in our library10.1016/j.addr.2019.04.008
241.
Lara S, et al. Identification of receptor binding to the biomolecular corona of nanoparticles. ACS Nano. 2017;11:1884-1893.
Not in our library10.1021/acsnano.6b07933
242.
Uva M, et al. On the mechanism of drug release from polysaccharide hydrogels cross-linked with magnetite nanoparticles by applying alternating magnetic fields: the case of DOXO delivery. Gels. 2015;1:24-43.
Not in our library10.3390/gels1010024
243.
Chen Y, Feng X. Gold nanoparticles for skin drug delivery. Int. J. Pharm. 2022;625:122122.
Not in our library10.1016/j.ijpharm.2022.122122
244.
Ghorbani, M. & Hamishehkar, H. Decoration of gold nanoparticles with thiolated pH-responsive polymeric (PEG-b-p(2-dimethylamio ethyl methacrylate-co-itaconic acid) shell: a novel platform for targeting of anticancer agent. Mater. Sci. Eng. C 81, 561–570 (2017).
Not in our library10.1016/j.msec.2017.08.021
245.
Dadfar SM, et al. Iron oxide nanoparticles: diagnostic, therapeutic and theranostic applications. Adv. Drug Deliv. Rev. 2019;138:302-325.
Not in our library10.1016/j.addr.2019.01.005
246.
Vaughan HJ, Green JJ, Tzeng SY. Cancer‐targeting nanoparticles for combinatorial nucleic acid delivery. Adv. Mater. 2019;32:e1901081.
Not in our library10.1002/adma.201901081
247.
Physiological and Pathological Factors Affecting Drug Delivery to the Brain by Nanoparticles · 2021
Not checked
248.
Li Y, et al. Co‐delivery of precisely prescribed multi‐prodrug combination by an engineered nanocarrier enables efficient individualized cancer chemotherapy. Adv. Mater. 2022;34:e2110490.
Not in our library10.1002/adma.202110490
249.
Shapira S, et al. A novel platform for attenuating immune hyperactivity using EXO‐CD24 in COVID‐19 and beyond. EMBO Mol. Med. 2022;14:e15997.
Not in our library10.15252/emmm.202215997
250.
Nebulized exosomes derived from allogenic adipose tissue mesenchymal stromal cells in patients with severe COVID-19: a pilot study · 2022
No notice
251.
Zou X, et al. EVs containing host restriction factor IFITM3 inhibited ZIKV infection of fetuses in pregnant mice through trans-placenta delivery. Mol. Ther. 2021;29:176-190.
Not in our library10.1016/j.ymthe.2020.09.026
252.
Exosome-mediated stable epigenetic repression of HIV-1 · 2021
Not checked
253.
Lawitz EJ, et al. BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial. Hepatology. 2021;75:912-923.
Not in our library10.1002/hep.32181
254.
Teng Y, et al. Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12. Mol. Ther. 2021;29:2424-2440.
Not in our library10.1016/j.ymthe.2021.05.005
255.
Zhang R, et al. sEVsRVG selectively delivers antiviral siRNA to fetus brain, inhibits ZIKV infection and mitigates ZIKV-induced microcephaly in mouse model. Mol. Ther. 2022;30:2078-2091.
Not in our library10.1016/j.ymthe.2021.10.009
256.
Yadavalli T, Shukla D. Role of metal and metal oxide nanoparticles as diagnostic and therapeutic tools for highly prevalent viral infections. Nanomedicine. 2017;13:219-230.
Not in our library10.1016/j.nano.2016.08.016
257.
Demchenko HO, Rusinchuk NM. Evaluation of the efficiency of interparticle interactions in nanosystems. J. Nanotechnol. 2019;2019:1-8.
Not in our library10.1155/2019/4270454
258.
Porous gold nanoparticles for attenuating infectivity of influenza A virus · 2020
Not checked
259.
Jeremiah SS, et al. Potent antiviral effect of silver nanoparticles on SARS-CoV-2. Biochem. Biophys. Res. Commun. 2020;533:195-200.
Not in our library10.1016/j.bbrc.2020.09.018
260.
Reina G, et al. Hard nanomaterials in time of viral pandemics. ACS Nano. 2020;14:9364-9388.
Not in our library10.1021/acsnano.0c04117
261.
Cagno V, et al. Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism. Nat. Mater. 2017;17:195-203.
Not in our library10.1038/nmat5053
262.
Silver Nanoparticles as Potential Antiviral Agents · 2011
No notice
263.
Aref ZF, et al. Clinical, biochemical and molecular evaluations of ivermectin mucoadhesive nanosuspension nasal spray in reducing upper respiratory symptoms of mild COVID-19. Int. J. Nanomed. 2021;16:4063-4072.
Not in our library10.2147/ijn.s313093
264.
Du T, et al. Glutathione-capped Ag2S nanoclusters inhibit coronavirus proliferation through blockage of viral RNA synthesis and budding. ACS Appl. Mater. Interfaces. 2018;10:4369-4378.
Not in our library10.1021/acsami.7b13811
265.
McGowan I, et al. Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment. Lancet HIV. 2016;3:e569-e578.
Not in our library10.1016/s2352-3018(16)30113-8
266.
Alavi M, Kamarasu P, McClements DJ, Moore MD. Metal and metal oxide-based antiviral nanoparticles: Properties, mechanisms of action, and applications. Adv. Colloid Interface Sci. 2022;306:102726.
Not in our library10.1016/j.cis.2022.102726
267.
Hamdi M, et al. Investigating the internalization and COVID-19 antiviral computational analysis of optimized nanoscale zinc oxide. ACS Omega. 2021;6:6848-6860.
Not in our library10.1021/acsomega.0c06046
268.
Baram-Pinto D, et al. Inhibition of herpes simplex virus type 1 infection by silver nanoparticles capped with mercaptoethane sulfonate. Bioconjug. Chem. 2009;20:1497-1502.
Not in our library10.1021/bc900215b
269.
Halder A, et al. Highly monodispersed gold nanoparticles synthesis and inhibition of herpes simplex virus infections. Mater. Sci. Eng. C. 2018;89:413-421.
Not in our library10.1016/j.msec.2018.04.005
270.
Khanal M, et al. Boronic acid-modified lipid nanocapsules: a novel platform for the highly efficient inhibition of hepatitis C viral entry. Nanoscale. 2015;7:1392-1402.
Not in our library10.1039/c4nr03875d
271.
Joonaki E, Hassanpouryouzband A, Heldt CL, Areo O. Surface chemistry can unlock drivers of surface stability of SARS-CoV-2 in a variety of environmental conditions. Chem. 2020;6:2135-2146.
Not in our library10.1016/j.chempr.2020.08.001
272.
Mosafer J, et al. Preparation, characterization and in vivo evaluation of alginate-coated chitosan and trimethylchitosan nanoparticles loaded with PR8 influenza virus for nasal immunization. Asian J. Pharm. 2019;14:216-221.
Not in our library10.1016/j.ajps.2018.04.005
273.
Liu H, et al. Preclinical evaluation of the saponin derivative GPI-0100 as an immunostimulating and dose-sparing adjuvant for pandemic influenza vaccines. Vaccine. 2011;29:2037-2043.
Not in our library10.1016/j.vaccine.2011.01.012
274.
Abbott TR, et al. Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell. 2020;181:865-876.
Not in our library10.1016/j.cell.2020.04.020
275.
Montague SJ, et al. Platelet activation by charged ligands and nanoparticles: platelet glycoprotein receptors as pattern recognition receptors. Platelets. 2021;32:1018-1030.
Not in our library10.1080/09537104.2021.1945571
276.
Zhang H, et al. Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling. Proc. Natl Acad. Sci. USA. 2021;118:e2005191118.
Not in our library10.1073/pnas.2005191118
277.
Yazdi AS, et al. Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β. Proc. Natl Acad. Sci. USA. 2010;107:19449-19454.
Not in our library10.1073/pnas.1008155107
278.
Du T, et al. Carbon dots as inhibitors of virus by activation of type I interferon response. Carbon. 2016;110:278-285.
Not in our library10.1016/j.carbon.2016.09.032
279.
Carbon Dots as Potent Antimicrobial Agents · 2020
No notice
280.
Barras A, et al. High efficiency of functional carbon nanodots as entry inhibitors of herpes simplex virus type 1. ACS Appl. Mater. Interfaces. 2016;8:9004-9013.
Not in our library10.1021/acsami.6b01681
281.
Wang J, et al. Pulmonary surfactant–biomimetic nanoparticles potentiate heterosubtypic influenza immunity. Science. 2020;367:eaau0810.
Not in our library10.1126/science.aau0810
282.
Tong T, et al. Glycyrrhizic‐acid‐based carbon dots with high antiviral activity by multisite inhibition mechanisms. Small. 2020;16:e1906206.
Not in our library10.1002/smll.201906206
283.
Li Y, et al. Silver nanoparticle based codelivery of oseltamivir to inhibit the activity of the H1N1 influenza virus through ROS-mediated signaling pathways. ACS Appl. Mater. Interfaces. 2016;8:24385-24393.
Not in our library10.1021/acsami.6b06613
284.
Kang J, Tahir A, Wang H, Chang J. Applications of nanotechnology in virus detection, tracking, and infection mechanisms. Wiley Interdiscip. Rev.-Nanomed. Nanobiotechnol. 2021;13:e1700.
Not in our library10.1002/wnan.1700
285.
Cheng R, et al. “Hepatitis virus indicator”––the simultaneous detection of hepatitis B and hepatitis C viruses based on the automatic particle enumeration. Biosens. Bioelectron. 2022;202:114001.
Not in our library10.1016/j.bios.2022.114001
286.
Chen H, et al. SERS imaging-based aptasensor for ultrasensitive and reproducible detection of influenza virus A. Biosens. Bioelectron. 2020;167:112496.
Not in our library10.1016/j.bios.2020.112496
287.
Hou J, et al. Rapid and reliable ultrasensitive detection of pathogenic H9N2 viruses through virus-binding phage nanofibers decorated with gold nanoparticles. Biosens. Bioelectron. 2023;237:115423.
Not in our library10.1016/j.bios.2023.115423
288.
Ganganboina AB, et al. Hollow magnetic-fluorescent nanoparticles for dual-modality virus detection. Biosens. Bioelectron. 2020;170:112680.
Not in our library10.1016/j.bios.2020.112680
289.
Ruiz‐Hitzky E, et al. Nanotechnology responses to COVID‐19. Adv. Healthc. 2020;9:e2000979.
Not in our library10.1002/adhm.202000979
290.
Draz MS, et al. Motion-based immunological detection of Zika virus using Pt-nanomotors and a cellphone. ACS Nano. 2018;12:5709-5718.
Not in our library10.1021/acsnano.8b01515
291.
Behrouzi K, Lin L. Gold nanoparticle based plasmonic sensing for the detection of SARS-CoV-2 nucleocapsid proteins. Biosens. Bioelectron. 2022;195:113669.
Not in our library10.1016/j.bios.2021.113669
292.
Ali MA, et al. Ultrarapid and ultrasensitive detection of SARS‐CoV‐2 antibodies in COVID‐19 patients via a 3D‐printed nanomaterial‐based biosensing platform. J. Med. Virol. 2022;94:5808-5826.
Not in our library10.1002/jmv.28075
293.
Vermisoglou E, et al. Human virus detection with graphene-based materials. Biosens. Bioelectron. 2020;166:112436.
Not in our library10.1016/j.bios.2020.112436
294.
Grinyte R, et al. Microbead QD-ELISA: microbead ELISA using biocatalytic formation of quantum dots for ultra high sensitive optical and electrochemical detection. ACS Appl. Mater. Interfaces. 2016;8:29252-29260.
Not in our library10.1021/acsami.6b08362
295.
Kurdekar A, et al. Comparative performance evaluation of carbon dot-based paper immunoassay on Whatman filter paper and nitrocellulose paper in the detection of HIV infection. Microfluid Nanofluidics. 2016;20:99.
Not in our library10.1007/s10404-016-1763-9
296.
Ye L, et al. Rapid colloidal gold immunochromatographic assay for the detection of SARS-CoV-2 total antibodies after vaccination. J. Mater. Chem. B. 2022;10:1786-1794.
Not in our library10.1039/d1tb02521j
297.
Sibai M, et al. Evaluation of SARS-CoV-2 total antibody detection via a lateral flow nanoparticle fluorescence immunoassay. J. Clin. Virol. 2021;139:104818.
Not in our library10.1016/j.jcv.2021.104818
298.
Wang M, Zhang R, Li J. CRISPR/cas systems redefine nucleic acid detection: Principles and methods. Biosens. Bioelectron. 2020;165:112430.
Not in our library10.1016/j.bios.2020.112430
299.
Fozouni P, et al. Amplification-free detection of SARS-CoV-2 with CRISPR-Cas13a and mobile phone microscopy. Cell. 2021;184:323-333.e329.
Not in our library10.1016/j.cell.2020.12.001
300.
Ultrasensitive and visual detection of SARS-CoV-2 using all-in-one dual CRISPR-Cas12a assay · 2020
No notice
301.
van Beljouw SPB, Sanders J, Rodríguez-Molina A, Brouns SJJ. RNA-targeting CRISPR–Cas systems. Nat. Rev. Microbiol. 2022;21:21-34.
Not in our library10.1038/s41579-022-00793-y
302.
Kaminski MM, et al. CRISPR-based diagnostics. Nat. Biomed. Eng. 2021;5:643-656.
Not in our library10.1038/s41551-021-00760-7
303.
Massively multiplexed nucleic acid detection with Cas13 · 2020
No notice
304.
Lu S, et al. Fast and sensitive detection of SARS-CoV-2 RNA using suboptimal protospacer adjacent motifs for Cas12a. Nat. Biomed. Eng. 2022;6:286-297.
Not in our library10.1038/s41551-022-00861-x
305.
Freije CA, et al. Programmable inhibition and detection of RNA viruses using Cas13. Mol. Cell. 2019;76:826-837.e811.
Not in our library10.1016/j.molcel.2019.09.013
306.
Tian Y, et al. CRISPR/Cas13a-assisted rapid and portable HBV DNA detection for low-level viremia patients. Emerg. Microbes Infect. 2023;12:e2177088.
Not in our library10.1080/22221751.2023.2177088
307.
Freije CA, Sabeti PC. Detect and destroy: CRISPR-based technologies for the response against viruses. Cell Host Microbe. 2021;29:689-703.
Not in our library10.1016/j.chom.2021.04.003
308.
Broughton JP, et al. CRISPR–Cas12-based detection of SARS-CoV-2. Nat. Biotechnol. 2020;38:870-874.
Not in our library10.1038/s41587-020-0513-4
309.
Patchsung M, et al. Clinical validation of a Cas13-based assay for the detection of SARS-CoV-2 RNA. Nat. Biomed. Eng. 2020;4:1140-1149.
Not in our library10.1038/s41551-020-00603-x
310.
Zhang J, et al. The construction of a novel nucleic acids detection microplatform based on the NSET for one-step detecting TK1-DNA and microRNA-21. Biosens. Bioelectron. 2017;97:26-33.
Not in our library10.1016/j.bios.2017.05.039
311.
Moitra P, et al. Selective naked-eye detection of SARS-CoV-2 mediated by N GEne Targeted Antisense Oligonucleotide Capped Plasmonic Nanoparticles. ACS Nano. 2020;14:7617-7627.
Not in our library10.1021/acsnano.0c03822
312.
Layqah LA, Eissa S. An electrochemical immunosensor for the corona virus associated with the Middle East respiratory syndrome using an array of gold nanoparticle-modified carbon electrodes. Mikrochim Acta. 2019;186:224.
Not in our library10.1007/s00604-019-3345-5
313.
Muhammad W, Zhai Z, Gao C. Antiviral activity of nanomaterials against coronaviruses. Macromol. Biosci. 2020;20:e2000196.
Not in our library10.1002/mabi.202000196
314.
Zhao Q, et al. A metal chelator as a plasmonic signal‐generation superregulator for ultrasensitive colorimetric bioassays of disease biomarkers. Adv. Sci. 2018;5:1800295.
Not in our library10.1002/advs.201800295
315.
Ahmeda SR, Nagyb É, Neethirajan S. Self-assembled star-shaped chiroplasmonic gold nanoparticles for an ultrasensitive chiro-immunosensor for viruses. RSC Adv. 2017;7:40849-40857.
Not in our library10.1039/c7ra07175b
316.
Yuan J, et al. Artificial intelligence-assisted enumeration of ultra-small viruses with dual dark-field plasmon resonance probes. Biosens. Bioelectron. 2022;199:113893.
Not in our library10.1016/j.bios.2021.113893
317.
Wen L, et al. Labeling the nucleocapsid of enveloped baculovirus with quantum dots for single-virus tracking. Biomaterials. 2014;35:2295-2301.
Not in our library10.1016/j.biomaterials.2013.11.069
318.
Duval JFL, van Leeuwen HP, Norde W, Town RM. Chemodynamic features of nanoparticles: application to understanding the dynamic life cycle of SARS-CoV-2 in aerosols and aqueous biointerfacial zones. Adv. Colloid Interface Sci. 2021;290:102400.
Not in our library10.1016/j.cis.2021.102400
319.
Detection of a single circulating tumor cell using a genetically engineered antibody-like phage nanofiber probe · 2021
Not checked
320.
Zhou X, et al. Phage-mediated counting by the naked eye of miRNA molecules at attomolar concentrations in a Petri dish. Nat. Mater. 2015;14:1058-1064.
Not in our library10.1038/nmat4377
321.
The importance of antimicrobial resistance in medical mycology · 2022
No notice
322.
Fernández J, Piano S, Bartoletti M, Wey EQ. Management of bacterial and fungal infections in cirrhosis: The MDRO challenge. J. Hepatol. 2021;75:S101-S117.
Not in our library10.1016/j.jhep.2020.11.010
323.
Franck CO, et al. Biopolymer-based carriers for DNA vaccine design. Angew. Chem. Int Ed. Engl. 2021;60:13225-13243.
Not in our library10.1002/anie.202010282
324.
Lee J, Arun Kumar S, Jhan YY, Bishop CJ. Engineering DNA vaccines against infectious diseases. Acta Biomater. 2018;80:31-47.
Not in our library10.1016/j.actbio.2018.08.033
325.
mRNA vaccine: a potential therapeutic strategy · 2021
No notice
326.
Muhammad A, et al. Bacterial ghosts as carriers of protein subunit and DNA-encoded antigens for vaccine applications. Expert Rev. Vaccines. 2014;11:97-116.
Not in our library10.1586/erv.11.149
327.
Micoli F, MacLennan CA. Outer membrane vesicle vaccines. Semin. Immunol. 2020;50:101433.
Not in our library10.1016/j.smim.2020.101433
328.
Meza-Segura M, et al. SepA enhances Shigella invasion of epithelial cells by degrading alpha-1 antitrypsin and producing a neutrophil chemoattractant. mBio. 2021;12:e0283321.
Not in our library10.1128/mbio.02833-21
329.
Mellbye B, Schuster M. The sociomicrobiology of antivirulence drug resistance: a proof of concept. mBio. 2011;2:e00131-00111.
Not in our library10.1128/mbio.00131-11
330.
Pereira VB, et al. DNA vaccines approach: from concepts to applications. World J. Vaccines. 2014;04:50-71.
Not in our library10.4236/wjv.2014.42008
331.
Simmons JD, et al. Immunological mechanisms of human resistance to persistent Mycobacterium tuberculosis infection. Nat. Rev. Immunol. 2018;18:575-589.
Not in our library10.1038/s41577-018-0025-3
332.
Dalirfardouei R, et al. A novel formulation of Mtb72F DNA vaccine for immunization against tuberculosis. Iran. J. Basic Med Sci. 2020;23:826-832.
Not in our library10.22038/ijbms.2020.41806.9881
333.
Chatzikleanthous D, O’Hagan DT, Adamo R. Lipid-based nanoparticles for delivery of vaccine adjuvants and antigens: toward multicomponent vaccines. Mol. Pharm. 2021;18:2867-2888.
Not in our library10.1021/acs.molpharmaceut.1c00447
334.
Chung YH, Cai H, Steinmetz NF. Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications. Adv. Drug Deliv. Rev. 2020;156:214-235.
Not in our library10.1016/j.addr.2020.06.024
335.
Li M, Yu D-H, Cai H. The synthetic antimicrobial peptide KLKL5KLK enhances the protection and efficacy of the combined DNA vaccine against Mycobacterium tuberculosis. DNA Cell Biol. 2008;27:405-413.
Not in our library10.1089/dna.2007.0693
336.
Advances in Chitosan-Based Nanoparticles for Drug Delivery · 2021
No notice
337.
Schwendener RA, Ludewig B, Cerny A, Engler O. Liposome-based vaccines. Methods Mol. Biol. 2010;605:163-175.
Not in our library10.1007/978-1-60327-360-2_11
338.
Baden LR, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 2021;384:403-416.
Not in our library10.1056/nejmoa2035389
339.
Lorenzi JCC, et al. Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis. BMC Biotechnol. 2010;10:77.
Not in our library10.1186/1472-6750-10-77
340.
Maruggi G, et al. Immunogenicity and protective efficacy induced by self-amplifying mRNA vaccines encoding bacterial antigens. Vaccine. 2017;35:361-368.
Not in our library10.1016/j.vaccine.2016.11.040
341.
Mayer RL, et al. Immunopeptidomics-based design of mRNA vaccine formulations against Listeria monocytogenes. Nat. Commun. 2022;13:6075.
Not in our library10.1038/s41467-022-33721-y
342.
Fan X-Y, Lowrie DB. Where are the RNA vaccines for TB? Emerg. Microbes Infect. 2021;10:1217-1218.
Not in our library10.1080/22221751.2021.1935328
343.
Schwechheimer C, Kuehn MJ. Outer-membrane vesicles from Gram-negative bacteria: biogenesis and functions. Nat. Rev. Microbiol. 2015;13:605-619.
Not in our library10.1038/nrmicro3525
344.
Outer Membrane Vesicles: Current Status and Future Direction of These Novel Vaccine Adjuvants · 2018
No notice
345.
Release of Staphylococcus aureus extracellular vesicles and their application as a vaccine platform · 2018
No notice
346.
Chen L, et al. Outer membrane vesicles displaying engineered glycotopes elicit protective antibodies. Proc. Natl Acad. Sci. USA. 2016;113:E3609-E3618.
Not in our library10.1073/pnas.1518311113
347.
Chen DJ, et al. Delivery of foreign antigens by engineered outer membrane vesicle vaccines. Proc. Natl Acad. Sci. USA. 2010;107:3099-3104.
Not in our library10.1073/pnas.0805532107
348.
Camacho AI, et al. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice. Vaccine. 2013;31:3288-3294.
Not in our library10.1016/j.vaccine.2013.05.020
349.
Gao W, et al. Modulating antibacterial immunity via bacterial membrane-coated nanoparticles. Nano Lett. 2015;15:1403-1409.
Not in our library10.1021/nl504798g
350.
Dickey SW, Cheung GYC, Otto M. Different drugs for bad bugs: antivirulence strategies in the age of antibiotic resistance. Nat. Rev. Drug Discov. 2017;16:457-471.
Not in our library10.1038/nrd.2017.23
351.
Angsantikul P, Fang RH, Zhang L. Toxoid vaccination against bacterial infection using cell membrane-coated nanoparticles. Bioconjug. Chem. 2017;29:604-612.
Not in our library10.1021/acs.bioconjchem.7b00692
352.
Hu C-MJ, Fang RH, Luk BT, Zhang L. Nanoparticle-detained toxins for safe and effective vaccination. Nat. Nanotechnol. 2013;8:933-938.
Not in our library10.1038/nnano.2013.254
353.
Wang F, et al. Nanoparticle‐based antivirulence vaccine for the management of methicillin‐resistant Staphylococcus aureus skin infection. Adv. Funct. Mater. 2016;26:1628-1635.
Not in our library10.1002/adfm.201505231
354.
Chen Y, et al. Broad‐spectrum neutralization of pore‐forming toxins with human erythrocyte membrane‐coated nanosponges. Adv. Healthc. 2018;7:e1701366.
Not in our library10.1002/adhm.201701366
355.
Hu C-MJ, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015;526:118-121.
Not in our library10.1038/nature15373
356.
Chen W, et al. Coating nanofiber scaffolds with beta cell membrane to promote cell proliferation and function. Nanoscale. 2016;8:10364-10370.
Not in our library10.1039/c6nr00535g
357.
Thamphiwatana S, et al. Macrophage-like nanoparticles concurrently absorbing endotoxins and proinflammatory cytokines for sepsis management. Proc. Natl Acad. Sci. USA. 2017;114:11488-11493.
Not in our library10.1073/pnas.1714267114
358.
Silver Nanoparticles and Their Antibacterial Applications · 2021
No notice
359.
Deshmukh SP, Patil SM, Mullani SB, Delekar SD. Silver nanoparticles as an effective disinfectant: a review. Mater. Sci. Eng. C. 2019;97:954-965.
Not in our library10.1016/j.msec.2018.12.102
360.
Ali S, et al. The avenue of fruit wastes to worth for synthesis of silver and gold nanoparticles and their antimicrobial application against foodborne pathogens: A review. Food Chem. 2021;359:129912.
Not in our library10.1016/j.foodchem.2021.129912
361.
Wang Z, et al. Activation of biologically relevant levels of reactive oxygen species by Au/g-C3N4 hybrid nanozyme for bacteria killing and wound disinfection. Biomaterials. 2017;113:145-157.
Not in our library10.1016/j.biomaterials.2016.10.041
362.
van Hengel IAJ, et al. Self-defending additively manufactured bone implants bearing silver and copper nanoparticles. J. Mater. Chem. B. 2020;8:1589-1602.
Not in our library10.1039/c9tb02434d
363.
Estes LM, et al. Characterization of a nitric oxide (NO) donor molecule and cerium oxide nanoparticle (CNP) interactions and their synergistic antimicrobial potential for biomedical applications. J. Colloid Interface Sci. 2021;586:163-177.
Not in our library10.1016/j.jcis.2020.10.081
364.
Nguyen T-K, et al. Rational design of single-chain polymeric nanoparticles that kill planktonic and biofilm bacteria. ACS Infect. Dis. 2017;3:237-248.
Not in our library10.1021/acsinfecdis.6b00203
365.
Bakhshandeh B, et al. New analytical methods using carbon-based nanomaterials for detection of Salmonella species as a major food poisoning organism in water and soil resources. Chemosphere. 2022;287:132243.
Not in our library10.1016/j.chemosphere.2021.132243
366.
Wang Y, Shukla A. Bacteria-responsive biopolymer-coated nanoparticles for biofilm penetration and eradication. Biomater. Sci. 2022;10:2831-2843.
Not in our library10.1039/d2bm00361a
367.
Kheiri S, Liu X, Thompson M. Nanoparticles at biointerfaces: antibacterial activity and nanotoxicology. Colloids Surf. B. 2019;184:110550.
Not in our library10.1016/j.colsurfb.2019.110550
368.
Webster T, Wang Q, Larese-Casanova P. Inhibition of various gram-positive and gram-negative bacteria growth on selenium nanoparticle coated paper towels. Int. J. Nanomed. 2015;10:2885-2894.
Not in our library10.2147/ijn.s78466
369.
Román LE, Gomez ED, Solís JL, Gómez MM. Antibacterial cotton fabric functionalized with copper oxide nanoparticles. Molecules. 2020;25:5802.
Not in our library10.3390/molecules25245802
370.
Costa EM, et al. Chitosan nanoparticles as alternative anti-staphylococci agents: Bactericidal, antibiofilm and antiadhesive effects. Mater. Sci. Eng. C. 2017;79:221-226.
Not in our library10.1016/j.msec.2017.05.047
371.
Gallo G, Schillaci D. Bacterial metal nanoparticles to develop new weapons against bacterial biofilms and infections. Appl. Microbiol. Biotechnol. 2021;105:5357-5366.
Not in our library10.1007/s00253-021-11418-4
372.
Zhang M, et al. Antimicrobial copper ion‐graphene oxide composite to inhibit Pseudomonas Aeruginosa keratitis in rabbits. MedComm – Biomater. Appl. 2023;2:e56.
Not in our library
373.
Tornero-Gutiérrez F, Ortiz-Ramírez JA, López-Romero E, Cuéllar-Cruz M. Materials used to prevent adhesion, growth, and biofilm formation of Candidaspecies. Med. Mycol. 2023;61:myad065.
Not in our library10.1093/mmy/myad065
374.
Naha PC, et al. Dextran-coated iron oxide nanoparticles as biomimetic catalysts for localized and pH-activated biofilm disruption. ACS Nano. 2019;13:4960-4971.
Not in our library10.1021/acsnano.8b08702
375.
dos Santos CA, Ingle AP, Rai M. The emerging role of metallic nanoparticles in food. Appl. Microbiol. Biotechnol. 2020;104:2373-2383.
Not in our library10.1007/s00253-020-10372-x
376.
Chlumsky O, et al. Antimicrobial properties of palladium and platinum nanoparticles: a new tool for combating food-borne pathogens. Int. J. Mol. Sci. 2021;22:7892.
Not in our library10.3390/ijms22157892
377.
Putra NE, et al. Preventing antibiotic-resistant infections: additively manufactured porous Ti6Al4V biofunctionalized with Ag and Fe nanoparticles. Int. J. Mol. Sci. 2022;23:13239.
Not in our library10.3390/ijms232113239
378.
Brennan SA, et al. Silver nanoparticles and their orthopaedic applications. Bone Jt. J. 2015;97-B:582-589.
Not in our library10.1302/0301-620x.97b5.33336
379.
Kalantari K, et al. Wound dressings functionalized with silver nanoparticles: promises and pitfalls. Nanoscale. 2020;12:2268-2291.
Not in our library10.1039/c9nr08234d
380.
López-Ruiz M, et al. L-arginine-containing mesoporous silica nanoparticles embedded in dental adhesive (Arg@MSN@DAdh) for targeting cariogenic bacteria. J. Nanobiotechnol. 2022;20:502.
Not in our library10.1186/s12951-022-01714-0
381.
Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv. Drug Deliv. Rev. 2013;65:1803-1815.
Not in our library10.1016/j.addr.2013.07.011
382.
Forier K, et al. Lipid and polymer nanoparticles for drug delivery to bacterial biofilms. J. Control Release. 2014;190:607-623.
Not in our library10.1016/j.jconrel.2014.03.055
383.
Agreles MAA, Cavalcanti IDL, Cavalcanti IMF. Synergism between metallic nanoparticles and antibiotics. Appl. Microbiol. Biotechnol. 2022;106:3973-3984.
Not in our library10.1007/s00253-022-12001-1
384.
Alavi M, Rai M. Recent advances in antibacterial applications of metal nanoparticles (MNPs) and metal nanocomposites (MNCs) against multidrug-resistant (MDR) bacteria. Expert Rev. Anti Infect. Ther. 2019;17:419-428.
Not in our library10.1080/14787210.2019.1614914
385.
Zheng T, et al. Co-assembled nanocomplexes comprising epigallocatechin gallate and berberine for enhanced antibacterial activity against multidrug resistant Staphylococcus aureus. Biomed. Pharmacother. 2023;163:114856.
Not in our library10.1016/j.biopha.2023.114856
386.
Alsakhawy SA, et al. Encapsulation of thymus vulgaris essential oil in caseinate/gelatin nanocomposite hydrogel: In vitro antibacterial activity and in vivo wound healing potential. Int. J. Pharm. 2022;628:122280.
Not in our library10.1016/j.ijpharm.2022.122280
387.
Wu J, et al. Mucus-permeable polymyxin B-hyaluronic acid/poly (lactic-co-glycolic acid) nanoparticle platform for the nebulized treatment of lung infections. J. Colloid Interface Sci. 2022;624:307-319.
Not in our library10.1016/j.jcis.2022.05.121
388.
Wu Y, Gao H, Liu J, Liang H. Chitosan nanoparticles efficiently enhance the dispersibility, stability and selective antibacterial activity of insoluble isoflavonoids. Int. J. Biol. Macromol. 2023;232:123420.
Not in our library10.1016/j.ijbiomac.2023.123420
389.
Paredes da Rocha N, et al. Highly water-soluble dapsone nanocrystals: towards innovative preparations for an undermined drug. Int. J. Pharm. 2023;630:122428.
Not in our library10.1016/j.ijpharm.2022.122428
390.
El-Housiny S, et al. Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study. Drug Deliv. 2017;25:78-90.
Not in our library10.1080/10717544.2017.1413444
391.
Anwar SK, et al. Curcumin nanoparticles: the topical antimycotic suspension treating oral candidiasis. Odontology. 2022;111:350-359.
Not in our library10.1007/s10266-022-00742-4
392.
Gounani Z, et al. Mesoporous silica nanoparticles carrying multiple antibiotics provide enhanced synergistic effect and improved biocompatibility. Colloids Surf. B. 2019;175:498-508.
Not in our library10.1016/j.colsurfb.2018.12.035
393.
Fernández‐Campos F, et al. Evaluation of novel nystatin nanoemulsion for skin candidosis infections. Mycoses. 2012;56:70-81.
Not in our library10.1111/j.1439-0507.2012.02202.x
394.
Cinteza L, et al. Chitosan-stabilized Ag nanoparticles with superior biocompatibility and their synergistic antibacterial effect in mixtures with essential oils. Nanomaterials. 2018;8:826.
Not in our library10.3390/nano8100826
395.
Xu Y, Li H, Li X, Liu W. What happens when nanoparticles encounter bacterial antibiotic resistance? Sci. Total Environ. 2023;876:162856.
Not in our library10.1016/j.scitotenv.2023.162856
396.
Osman N, et al. Surface modification of nano‐drug delivery systems for enhancing antibiotic delivery and activity. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2021;14:e1758.
Not in our library10.1002/wnan.1758
397.
Vanamala K, et al. Folate functionalized lipid nanoparticles for targeted therapy of methicillin-resistant Staphylococcus aureus. Pharmaceutics. 2021;13:1791.
Not in our library10.3390/pharmaceutics13111791
398.
Muppidi K, Wang J, Betageri G, Pumerantz AS. PEGylated liposome encapsulation increases the lung tissue concentration of vancomycin. Antimicrob. Agents Chemother. 2011;55:4537-4542.
Not in our library10.1128/aac.00713-11
399.
Induction of mouse melioidosis with meningitis by CD11b+ phagocytic cells harboring intracellular B. pseudomallei as a Trojan horse. · 2013
Not checked
400.
Nguyen L, Pieters J. The Trojan Horse: survival tactics of pathogenic mycobacteria in macrophages. Trends Cell Biol. 2005;15:269-276.
Not in our library10.1016/j.tcb.2005.03.009
401.
Zou X, et al. Natural antibacterial agent-based nanoparticles for effective treatment of intracellular MRSA infection. Acta Biomater. 2023;169:410-421.
Not in our library10.1016/j.actbio.2023.08.004
402.
Li X, Chen D, Xie S. Current progress and prospects of organic nanoparticles against bacterial biofilm. Adv. Colloid Interface Sci. 2021;294:102475.
Not in our library10.1016/j.cis.2021.102475
403.
Dey N, et al. Role of nanomaterials in deactivating multiple drug resistance efflux pumps – a review. Environ. Res. 2022;204:111968.
Not in our library10.1016/j.envres.2021.111968
404.
Chwalibog, et al. Visualization of interaction between inorganic nanoparticles and bacteria or fungi. Int. J. Nanomed. 2010;5:1085-1094.
Not in our library10.2147/ijn.s13532
405.
Ye Y, et al. Cell wall destruction and internal cascade synergistic antifungal strategy for fungal keratitis. ACS Nano. 2022;16:18729-18745.
Not in our library10.1021/acsnano.2c07444
406.
Radovic-Moreno AF, et al. Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics. ACS Nano. 2012;6:4279-4287.
Not in our library10.1021/nn3008383
407.
Yang L, et al. pH-Responsive hyperbranched polymer nanoparticles to combat intracellular infection by disrupting bacterial wall and regulating macrophage polarization. Biomacromolecules. 2022;23:4370-4378.
Not in our library10.1021/acs.biomac.2c00823
408.
Hou S, et al. Metabolic labeling mediated targeting and thermal killing of gram‐positive bacteria by self‐reporting janus magnetic nanoparticles. Small. 2020;17:e2006357.
Not in our library10.1002/smll.202006357
409.
Astodrimer sodium antiviral nasal spray for reducing respiratory infections is safe and well tolerated in a randomized controlled trial · 2022
Not checked
410.
A phase 2, double-blind, multicenter, randomized, placebo-controlled, dose‑ranging study of the efficacy and safety of Astodrimer Gel for the treatment of bacterial vaginosis. · 2020
Not checked
411.
Thompson RN, Brooks-Pollock E. Detection, forecasting and control of infectious disease epidemics: modelling outbreaks in humans, animals and plants. Philos. Trans. R. Soc. Lond., B, Biol. Sci. 2019;374:20190038.
Not in our library10.1098/rstb.2019.0038
412.
Phakatkar AH, et al. In situ microscopic studies on the interaction of multi-principal element nanoparticles and bacteria. ACS Nano. 2023;17:5880-5893.
Not in our library10.1021/acsnano.2c12799
413.
Linklater DP, et al. Antibacterial action of nanoparticles by lethal stretching of bacterial cell membranes. Adv. Mater. 2020;32:e2005679.
Not in our library10.1002/adma.202005679
414.
Kim D, et al. Selective killing of pathogenic bacteria by antimicrobial silver nanoparticle—cell wall binding domain conjugates. ACS Appl. Mater. Interfaces. 2018;10:13317-13324.
Not in our library10.1021/acsami.8b00181
415.
Khare T, et al. Embelin-loaded chitosan gold nanoparticles interact synergistically with ciprofloxacin by inhibiting efflux pumps in multidrug-resistant Pseudomonas aeruginosa and Escherichia coli. Environ. Res. 2021;199:111321.
Not in our library10.1016/j.envres.2021.111321
416.
Xu Y, et al. CeO2 nanoparticles-regulated plasmid uptake and bioavailability for reducing transformation of extracellular antibiotic resistance genes. Nanomaterials. 2023;13:969.
Not in our library10.3390/nano13060969
417.
Ruiz-Fresneda MA, et al. Exploring antibacterial activity and bacterial-mediated allotropic transition of differentially coated selenium nanoparticles. ACS Appl. Mater. Interfaces. 2023;15:29958-29970.
Not in our library10.1021/acsami.3c05100
418.
Wang Z, et al. Multifunctional gold–silver–carbon quantum dots nano-hybrid composite: advancing antibacterial wound healing and cell proliferation. ACS Appl. Mater. Interfaces. 2023;15:40241-40254.
Not in our library10.1021/acsami.3c07625
419.
Ezraty B, Gennaris A, Barras F, Collet J-F. Oxidative stress, protein damage and repair in bacteria. Nat. Rev. Microbiol. 2017;15:385-396.
Not in our library10.1038/nrmicro.2017.26
420.
Yang D, et al. Nanozymes used for antimicrobials and their applications. Colloids Surf. B. 2020;195:111252.
Not in our library10.1016/j.colsurfb.2020.111252
421.
Mo F, et al. Recent advances in nanozymes for bacteria-infected wound therapy. Int. J. Nanomed. 2022;17:5947-5990.
Not in our library10.2147/ijn.s382796
422.
Surface-bound reactive oxygen species generating nanozymes for selective antibacterial action · 2021
No notice
423.
Sasaninia K, et al. Topical absorption of glutathione–cyclodextrin nanoparticle complex in healthy human subjects improves immune response against Mycobacterium avium infection. Antioxidants. 2023;12:1375.
Not in our library10.3390/antiox12071375
424.
Huang Y, et al. Stimuli‐responsive nanoplatforms for antibacterial applications. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2022;14:e1775.
Not in our library10.1002/wnan.1775
425.
Albayaty YN, et al. Enzyme responsive copolymer micelles enhance the anti-biofilm efficacy of the antiseptic chlorhexidine. Int. J. Pharm. 2019;566:329-341.
Not in our library10.1016/j.ijpharm.2019.05.069
426.
Hu C-MJ, et al. A biomimetic nanosponge that absorbs pore-forming toxins. Nat. Nanotechnol. 2013;8:336-340.
Not in our library10.1038/nnano.2013.54
427.
Meng Y, et al. Reactive metal boride nanoparticles trap lipopolysaccharide and peptidoglycan for bacteria-infected wound healing. Nat. Commun. 2022;13:7353.
Not in our library10.1038/s41467-022-35050-6
428.
Hajipour MJ, et al. Nanotechnology for targeted detection and removal of bacteria: opportunities and challenges. Adv. Sci. 2021;8:e2100556.
Not in our library10.1002/advs.202100556
429.
Yang X, et al. D-alanyl-D-alanine-modified gold nanoparticles form a broad-spectrum sensor for bacteria. Theranostics. 2018;8:1449-1457.
Not in our library10.7150/thno.22540
430.
Liu C, et al. Quantification of circulating Mycobacterium tuberculosis antigen peptides allows rapid diagnosis of active disease and treatment monitoring. Proc. Natl Acad. Sci. USA. 2017;114:3969-3974.
Not in our library10.1073/pnas.1621360114
431.
Zhao Z, et al. Bacteria-activated theranostic nanoprobes against methicillin-resistant Staphylococcus aureus infection. ACS nano. 2017;11:4428-4438.
Not in our library10.1021/acsnano.7b00041
432.
Khan SA, et al. Targeted highly sensitive detection of multi-drug resistant salmonella DT104 using gold nanoparticles. ChemComm. 2011;47:9444-9446.
Not in our library10.1039/c1cc13199k
433.
Naidoo R, et al. Surface-immobilization of chromatographically purified bacteriophages for the optimized capture of bacteria. Bacteriophage. 2014;2:15-24.
Not in our library10.4161/bact.19079
434.
Imai M, et al. Dark-field microscopic detection of bacteria using bacteriophage-immobilized SiO2@AuNP core–shell nanoparticles. Anal. Chem. 2019;91:12352-12357.
Not in our library10.1021/acs.analchem.9b02715
435.
Duncan B, et al. Sensing by smell: nanoparticle–enzyme sensors for rapid and sensitive detection of bacteria with olfactory output. ACS Nano. 2017;11:5339-5343.
Not in our library10.1021/acsnano.7b00822
436.
Plasmonic silver nanoshells for drug and metabolite detection · 2017
No notice
437.
Najer A, et al. Nanomimics of host cell membranes block invasion and expose invasive malaria parasites. ACS Nano. 2014;8:12560-12571.
Not in our library10.1021/nn5054206
438.
Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial · 2021
No notice
439.
Venkatraman N, et al. Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M™. Vaccine. 2017;35:6208-6217.
Not in our library10.1016/j.vaccine.2017.09.028
440.
Gola A, et al. Prime and target immunization protects against liver-stage malaria in mice. Sci. Transl. Med. 2018;10:eaap9128.
Not in our library10.1126/scitranslmed.aap9128
441.
Kamaraj C, et al. Biosynthesis and extrinsic toxicity of copper oxide nanoparticles against cattle parasites: an eco-friendly approach. Environ. Res. 2022;214:114009.
Not in our library10.1016/j.envres.2022.114009
442.
Salinas ND, et al. A potent and durable malaria transmission-blocking vaccine designed from a single-component 60-copy Pfs230D1 nanoparticle. NPJ Vaccines. 2023;8:124.
Not in our library10.1038/s41541-023-00709-8
443.
Healy SA, et al. Pfs230 yields higher malaria transmission–blocking vaccine activity than Pfs25 in humans but not mice. J. Clin. Investig. 2021;131:e146221.
Not in our library10.1172/jci146221
444.
Waris A, et al. Applications of various types of nanomaterials for the treatment of neurological disorders. Nanomaterials. 2022;12:2140.
Not in our library10.3390/nano12132140
445.
Murugesan C, Manivannan P, Gangatharan M. Pros and cons in prion diseases abatement: Insights from nanomedicine and transmissibility patterns. Int. J. Biol. Macromol. 2020;145:21-27.
Not in our library10.1016/j.ijbiomac.2019.12.150
446.
Kumar J, et al. Detection of amyloid fibrils in Parkinson’s disease using plasmonic chirality. Proc. Natl Acad. Sci. USA. 2018;115:3225-3230.
Not in our library10.1073/pnas.1721690115
447.
Lasmezas CI, et al. A visual dual-aptamer logic gate for sensitive discrimination of prion diseases-associated isoform with reusable magnetic microparticles and fluorescence quantum dots. PLoS ONE. 2013;8:e53935.
Not in our library10.1371/journal.pone.0053935
448.
Sorokina SA, Stroylova YY, Shifrina ZB, Muronetz VI. Disruption of amyloid prion protein aggregates by cationic pyridylphenylene dendrimers. Macromol. Biosci. 2015;16:266-275.
Not in our library10.1002/mabi.201500268
449.
Ganugula R, et al. A highly potent lymphatic system–targeting nanoparticle cyclosporine prevents glomerulonephritis in mouse model of lupus. Sci. Adv. 2020;6:eabb3900.
Not in our library10.1126/sciadv.abb3900
450.
Abuelella KE, Abd-Allah H, Soliman SM, Abdel-Mottaleb MMA. Skin targeting by chitosan/hyaluronate hybrid nanoparticles for the management of irritant contact dermatitis: In vivo therapeutic efficiency in mouse-ear dermatitis model. Int. J. Biol. Macromol. 2023;232:123458.
Not in our library10.1016/j.ijbiomac.2023.123458
451.
Rhein modulates host purine metabolism in intestine through gut microbiota and ameliorates experimental colitis · 2020
No notice
452.
Park J, et al. Tolerogenic nanovaccine for prevention and treatment of autoimmune encephalomyelitis. Adv. Mater. 2022;35:e2202670.
Not in our library10.1002/adma.202202670
453.
Wang P, et al. Hyaluronic acid-based M1 macrophage targeting and environmental responsive drug releasing nanoparticle for enhanced treatment of rheumatoid arthritis. Carbohydr. Polym. 2023;316:121018.
Not in our library10.1016/j.carbpol.2023.121018
454.
Jain P, Kathuria H, Momin M. Clinical therapies and nano drug delivery systems for urinary bladder cancer. Pharmacol. Ther. 2021;226:107871.
Not in our library10.1016/j.pharmthera.2021.107871
455.
Ma X, et al. Bioengineered nanogels for cancer immunotherapy. Chem. Soc. Rev. 2022;51:5136-5174.
Not in our library10.1039/d2cs00247g
456.
Anti-ICAM-1 antibody-modified nanostructured lipid carriers: a pulmonary vascular endothelium-targeted device for acute lung injury therapy · 2018
Not checked
457.
Zhu J, et al. Surface coating of pulmonary siRNA delivery vectors enabling mucus penetration, cell targeting, and intracellular radical scavenging for enhanced acute lung injury therapy. ACS Appl. Mater. Interfaces. 2022;14:5090-5100.
Not in our library10.1021/acsami.1c23069
458.
Lamson NG, Berger A, Fein KC, Whitehead KA. Anionic nanoparticles enable the oral delivery of proteins by enhancing intestinal permeability. Nat. Biomed. Eng. 2019;4:84-96.
Not in our library10.1038/s41551-019-0465-5
459.
Insights into Protein–Ligand Interactions: Mechanisms, Models, and Methods · 2016
No notice
460.
Tietjen GT, Bracaglia LG, Saltzman WM, Pober JS. Focus on Fundamentals: Achieving Effective Nanoparticle Targeting. Trends Mol. Med. 2018;24:598-606.
Not in our library10.1016/j.molmed.2018.05.003
461.
Chandrupatla DMSH, et al. The folate receptor β as a macrophage-mediated imaging and therapeutic target in rheumatoid arthritis. Drug Deliv. Transl. Res. 2018;9:366-378.
Not in our library10.1007/s13346-018-0589-2
462.
Lu YJ, et al. Targeting folate receptor beta on monocytes/macrophages renders rapid inflammation resolution independent of root causes. Cell Rep. Med. 2021;2:100422.
Not in our library10.1016/j.xcrm.2021.100422
463.
Wang Y, et al. Microvesicle-camouflaged biomimetic nanoparticles encapsulating a metal-organic framework for targeted rheumatoid arthritis therapy. J. Nanobiotechnol. 2022;20:253.
Not in our library10.1186/s12951-022-01447-0
464.
Thomas TP, et al. Folate‐targeted nanoparticles show efficacy in the treatment of inflammatory arthritis. Arthritis Rheumatol. 2011;63:2671-2680.
Not in our library10.1002/art.30459
465.
Feng Y, et al. Immune-microenvironment modulatory polyurethane-hyaluronic acid hybrid hydrogel scaffolds for diabetic wound treatment. Carbohydr. Polym. 2023;320:121238.
Not in our library10.1016/j.carbpol.2023.121238
466.
Lee WH, et al. Hyaluronic acid nanoparticles as a topical agent for treating psoriasis. ACS Nano. 2022;16:20057-20074.
Not in our library10.1021/acsnano.2c07843
467.
Bayarsaikhan G, Bayarsaikhan D, Lee J, Lee B. Targeting scavenger receptors in inflammatory disorders and oxidative stress. Antioxidants. 2022;11:936.
Not in our library10.3390/antiox11050936
468.
Gong T, et al. Palmitic acid-modified bovine serum albumin nanoparticles target scavenger receptor-A on activated macrophages to treat rheumatoid arthritis. Biomaterials. 2020;258:120296.
Not in our library10.1016/j.biomaterials.2020.120296
469.
Heo R, et al. Dextran sulfate nanoparticles as a theranostic nanomedicine for rheumatoid arthritis. Biomaterials. 2017;131:15-26.
Not in our library10.1016/j.biomaterials.2017.03.044
470.
Park EJ, Yuki Y, Kiyono H, Shimaoka M. Structural basis of blocking integrin activation and deactivation for anti-inflammation. J. Biomed. Sci. 2015;22:51.
Not in our library10.1186/s12929-015-0159-6
471.
Fu C, et al. Understanding the mechanical properties of Antheraea Pernyi silk—from primary structure to condensed structure of the protein. Adv. Funct. Mater. 2011;21:729-737.
Not in our library10.1002/adfm.201001046
472.
Rodriguez-Nogales A, et al. Intestinal anti-inflammatory effects of RGD-functionalized silk fibroin nanoparticles in trinitrobenzenesulfonic acid-induced experimental colitis in rats. Int. J. Nanomed. 2016;11:5945-5958.
Not in our library10.2147/ijn.s116479
473.
Kuwada T, et al. Identification of an anti-integrin αvβ6 autoantibody in patients with ulcerative colitis. Gastroenterology. 2021;160:2383-2394.e2321.
Not in our library10.1053/j.gastro.2021.02.019
474.
Ma Y, et al. Oral nanotherapeutics based on Antheraea pernyi silk fibroin for synergistic treatment of ulcerative colitis. Biomaterials. 2022;282:121410.
Not in our library10.1016/j.biomaterials.2022.121410
475.
Targeted apoptosis of macrophages and osteoclasts in arthritic joints is effective against advanced inflammatory arthritis · 2021
Corrected
476.
Liu L, et al. Secreted protein acidic and rich in cysteine mediated biomimetic delivery of methotrexate by albumin-based nanomedicines for rheumatoid arthritis therapy. ACS Nano. 2019;13:5036-5048.
Not in our library10.1021/acsnano.9b01710
477.
Zhang M, et al. Edible ginger-derived nanoparticles: a novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer. Biomaterials. 2016;101:321-340.
Not in our library10.1016/j.biomaterials.2016.06.018
478.
Ju S, et al. Grape exosome-like nanoparticles induce intestinal stem cells and protect mice from DSS-induced colitis. Mol. Ther. 2013;21:1345-1357.
Not in our library10.1038/mt.2013.64
479.
Edible exosome-like nanoparticles from portulaca oleracea L mitigate DSS-induced colitis via facilitating double-positive CD4+CD8+T cells expansion · 2023
No notice
480.
Huang Y-F, et al. Nanoparticle-mediated IgE−receptor aggregation and signaling in RBL mast cells. J. Am. Chem. Soc. 2009;131:17328-17334.
Not in our library10.1021/ja907125t
481.
Mendanha D, Vieira de Castro J, Ferreira H, Neves NM. Biomimetic and cell-based nanocarriers – new strategies for brain tumor targeting. J. Control Release. 2021;337:482-493.
Not in our library10.1016/j.jconrel.2021.07.047
482.
Ma Q, et al. Calming cytokine storm in pneumonia by targeted delivery of TPCA-1 using platelet-derived extracellular vesicles. Matter. 2020;3:287-301.
Not in our library10.1016/j.matt.2020.05.017
483.
Gao, M. et al. Erythrocyte‐membrane‐enveloped perfluorocarbon as nanoscale artificial red blood cells to relieve tumor hypoxia and enhance cancer radiotherapy. Adv. Mater. 29, 10.1002/adma.201701429 (2017).
Not in our library10.1002/adma.201701429
484.
Biomimetic nanoparticles for inflammation targeting · 2018
Not checked
485.
Oroojalian F, et al. Immune cell membrane‐coated biomimetic nanoparticles for targeted cancer therapy. Small. 2021;17:e2006484.
Not in our library10.1002/smll.202006484
486.
Macrophage membrane functionalized biomimetic nanoparticles for targeted anti-atherosclerosis applications · 2021
No notice
487.
Sha X, et al. Pro-efferocytic macrophage membrane biomimetic nanoparticles for the synergistic treatment of atherosclerosis via competition effect. J. Nanobiotechnol. 2022;20:506.
Not in our library10.1186/s12951-022-01720-2
488.
Li M, et al. Platelet membrane biomimetic magnetic nanocarriers for targeted delivery and in situ generation of nitric oxide in early ischemic stroke. ACS Nano. 2020;14:2024-2035.
Not in our library10.1021/acsnano.9b08587
489.
Yang N, et al. Peptide-anchored neutrophil membrane-coated biomimetic nanodrug for targeted treatment of rheumatoid arthritis. J. Nanobiotechnol. 2023;21:13.
Not in our library10.1186/s12951-023-01773-x
490.
Liu Y, et al. Neutrophil-membrane-coated biomineralized metal–organic framework nanoparticles for atherosclerosis treatment by targeting gene silencing. ACS Nano. 2023;17:7721-7732.
Not in our library10.1021/acsnano.3c00288
491.
Nelson A. Engineering interactions. Nat. Mater. 2008;7:523-525.
Not in our library10.1038/nmat2214
492.
Mao L, et al. Stimuli-responsive polymeric nanovaccines toward next-generation immunotherapy. ACS Nano. 2023;17:9826-9849.
Not in our library10.1021/acsnano.3c02273
493.
Tan J, et al. Anti-inflammatory polymersomes of redox-responsive polyprodrug amphiphiles with inflammation-triggered indomethacin release characteristics. Biomaterials. 2018;178:608-619.
Not in our library10.1016/j.biomaterials.2018.03.035
494.
Pu H-L, et al. Nanoparticles with dual responses to oxidative stress and reduced pH for drug release and anti-inflammatory applications. ACS Nano. 2014;8:1213-1221.
Not in our library10.1021/nn4058787
495.
Xu Y, et al. Glycogen-based pH and redox sensitive nanoparticles with ginsenoside Rh2 for effective treatment of ulcerative colitis. Biomaterials. 2022;280:121077.
Not in our library10.1016/j.biomaterials.2021.121077
496.
Li F, et al. Stimuli-responsive nano-assemblies for remotely controlled drug delivery. J. Control Release. 2020;322:566-592.
Not in our library10.1016/j.jconrel.2020.03.051
497.
Ni R, et al. Reactive oxygen species-responsive dexamethasone-loaded nanoparticles for targeted treatment of rheumatoid arthritis via suppressing the iRhom2/TNF-α/BAFF signaling pathway. Biomaterials. 2020;232:119730.
Not in our library10.1016/j.biomaterials.2019.119730
498.
Muhammad W, et al. ROS-responsive polymer nanoparticles with enhanced loading of dexamethasone effectively modulate the lung injury microenvironment. Acta Biomater. 2022;148:258-270.
Not in our library10.1016/j.actbio.2022.06.024
499.
Pu Y, et al. Sono‐controllable and ROS‐sensitive CRISPR‐Cas9 genome editing for augmented/synergistic ultrasound tumor nanotherapy. Adv. Mater. 2021;33:e2104641.
Not in our library10.1002/adma.202104641
500.
Shi C, et al. Trojan horse nanocapsule enabled in situ modulation of the phenotypic conversion of Th17 cells to treg cells for the treatment of multiple sclerosis in mice. Adv. Mater. 2023;35:e2210262.
Not in our library10.1002/adma.202210262
501.
He M, et al. Erythrocyte-membrane-enveloped biomineralized metal–organic framework nanoparticles enable intravenous glucose-responsive insulin delivery. ACS Appl. Mater. Interfaces. 2021;13:19648-19659.
Not in our library10.1021/acsami.1c01943
502.
Naeem M, et al. Colitis-targeted hybrid nanoparticles-in-microparticles system for the treatment of ulcerative colitis. Acta Biomater. 2020;116:368-382.
Not in our library10.1016/j.actbio.2020.09.017
503.
Cheng Y, et al. pH-Responsive multifunctional theranostic rapamycin-loaded nanoparticles for imaging and treatment of acute ischemic stroke. ACS Appl. Mater. Interfaces. 2021;13:56909-56922.
Not in our library10.1021/acsami.1c16530
504.
Nathan DM. The Diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Diabetes Care. 2014;37:9-16.
Not in our library10.2337/dc13-2112
505.
Yang J, Cao Z. Glucose-responsive insulin release: analysis of mechanisms, formulations, and evaluation criteria. J. Control Release. 2017;263:231-239.
Not in our library10.1016/j.jconrel.2017.01.043
506.
Zhao Y, Trewyn BG, Slowing II, Lin VSY. Mesoporous silica nanoparticle-based double drug delivery system for glucose-responsive controlled release of insulin and cyclic AMP. J. Am. Chem. Soc. 2009;131:8398-8400.
Not in our library10.1021/ja901831u
507.
Chou DH-C, et al. Glucose-responsive insulin activity by covalent modification with aliphatic phenylboronic acid conjugates. Proc. Natl Acad. Sci. USA. 2015;112:2401-2406.
Not in our library10.1073/pnas.1424684112
508.
High drug-loading gold nanoclusters for responsive glucose control in type 1 diabetes · 2019
Not checked
509.
Ali A, et al. Glucose-responsive chitosan nanoparticle/poly(vinyl alcohol) hydrogels for sustained insulin release in vivo. ACS Appl. Mater. Interfaces. 2023;15:32240-32250.
Not in our library10.1021/acsami.3c05031
510.
Zhang Y, et al. Surface-anchored microbial enzyme-responsive solid lipid nanoparticles enabling colonic budesonide release for ulcerative colitis treatment. J. Nanobiotechnol. 2023;21:145.
Not in our library10.1186/s12951-023-01889-0
511.
Chen S-Q, et al. Chitosan-modified lipid nanodrug delivery system for the targeted and responsive treatment of ulcerative colitis. Carbohydr. Polym. 2020;230:115613.
Not in our library10.1016/j.carbpol.2019.115613
512.
Luo Z, et al. Intracellular redox-activated anticancer drug delivery by functionalized hollow mesoporous silica nanoreservoirs with tumor specificity. Biomaterials. 2014;35:7951-7962.
Not in our library10.1016/j.biomaterials.2014.05.058
513.
Vazzana M, et al. Tramadol hydrochloride: pharmacokinetics, pharmacodynamics, adverse side effects, co-administration of drugs and new drug delivery systems. Biomed. Pharmacother. 2015;70:234-238.
Not in our library10.1016/j.biopha.2015.01.022
514.
Saito E, et al. Modulating lung immune cells by pulmonary delivery of antigen-specific nanoparticles to treat autoimmune disease. Sci. Adv. 2020;6:eabc9317.
Not in our library10.1126/sciadv.abc9317
515.
Zhang M, et al. Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment. J. Control Release. 2022;352:422-437.
Not in our library10.1016/j.jconrel.2022.10.020
516.
Khan ZA, Tripathi R, Mishra B. Methotrexate: a detailed review on drug delivery and clinical aspects. Expert Opin. Drug Deliv. 2012;9:151-169.
Not in our library10.1517/17425247.2012.642362
517.
Hoes JN, Jacobs JWG, Buttgereit F, Bijlsma JWJ. Current view of glucocorticoid co-therapy with DMARDs in rheumatoid arthritis. Nat. Rev. Rheumatol. 2010;6:693-702.
Not in our library10.1038/nrrheum.2010.179
518.
Jia Z, et al. Structural optimization of HPMA copolymer-based dexamethasone prodrug for improved treatment of inflammatory arthritis. J. Control Release. 2020;324:560-573.
Not in our library10.1016/j.jconrel.2020.05.028
519.
Ren S, et al. Acupoint nanocomposite hydrogel for simulation of acupuncture and targeted delivery of triptolide against rheumatoid arthritis. J. Nanobiotechnol. 2021;19:409.
Not in our library10.1186/s12951-021-01157-z
520.
Lorscheider M, et al. Dexamethasone palmitate nanoparticles: an efficient treatment for rheumatoid arthritis. J. Control Release. 2019;296:179-189.
Not in our library10.1016/j.jconrel.2019.01.015
521.
Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv. Drug Deliv. Rev. 2013;65:822-832.
Not in our library10.1016/j.addr.2012.10.007
522.
Wang X, et al. Oral delivery of anti-TNF antibody shielded by natural polyphenol-mediated supramolecular assembly for inflammatory bowel disease therapy. Theranostics. 2020;10:10808-10822.
Not in our library10.7150/thno.47601
523.
Zeng Z, et al. Stimuli-responsive self-assembled dendrimers for oral protein delivery. J. Control Release. 2019;315:206-213.
Not in our library10.1016/j.jconrel.2019.10.049
524.
Mai Y, et al. Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis. J. Control Release. 2022;349:354-366.
Not in our library10.1016/j.jconrel.2022.07.006
525.
Luo L, et al. Controlled release of corticosteroid with biodegradable nanoparticles for treating experimental autoimmune uveitis. J. Control Release. 2019;296:68-80.
Not in our library10.1016/j.jconrel.2019.01.018
526.
Moura RP, et al. Functionalized retinoic acid lipid nanocapsules promotes a two-front attack on inflammation and lack of demyelination on neurodegenerative disorders. J. Control Release. 2023;358:43-58.
Not in our library10.1016/j.jconrel.2023.04.034
527.
Zhang J, et al. “Two-birds-one-stone” colon-targeted nanomedicine treats ulcerative colitis via remodeling immune microenvironment and anti-fibrosis. J. Nanobiotechnol. 2022;20:389.
Not in our library10.1186/s12951-022-01598-0
528.
Lee Y, et al. Brain gene delivery using histidine and arginine-modified dendrimers for ischemic stroke therapy. J. Control Release. 2021;330:907-919.
Not in our library10.1016/j.jconrel.2020.10.064
529.
Rachamalla HK, et al. Skin-permeable nano-lithocholic lipidoid efficiently alleviates psoriasis-like chronic skin inflammations. ACS Appl. Mater. Interfaces. 2022;14:14859-14870.
Not in our library10.1021/acsami.1c19180
530.
Li M, et al. Deep eutectic solvents—Hydrogels for the topical management of rheumatoid arthritis. J. Control Release. 2023;354:664-679.
Not in our library10.1016/j.jconrel.2023.01.050
531.
Martins JP, et al. Engineered multifunctional albumin‐decorated porous silicon nanoparticles for FcRn translocation of insulin. Small. 2018;14:e1800462.
Not in our library10.1002/smll.201800462
532.
Sun W, et al. FcRn‐targeting and ROS‐responsive Fedratinib‐incorporated nanoparticles alleviate asthma by inducing eosinophil apoptosis. Allergy. 2022;78:1659-1663.
Not in our library10.1111/all.15575
533.
Hu C-MJ, et al. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc. Natl Acad. Sci. USA. 2011;108:10980-10985.
Not in our library10.1073/pnas.1106634108
534.
Qin X, et al. Inflammation-responsive nanoparticles suppress lymphatic clearance for prolonged arthritis therapy. J. Control Release. 2022;352:700-711.
Not in our library10.1016/j.jconrel.2022.11.005
535.
Lin Y, et al. Multifunctional nanoparticles of sinomenine hydrochloride for treat-to-target therapy of rheumatoid arthritis via modulation of proinflammatory cytokines. J. Control Release. 2022;348:42-56.
Not in our library10.1016/j.jconrel.2022.05.016
536.
Zhang M-Z, et al. Inhibition of 11β–hydroxysteroid dehydrogenase type II selectively blocks the tumor COX-2 pathway and suppresses colon carcinogenesis in mice and humans. J. Clin. Investig. 2009;119:876-885.
Not in our library10.1172/jci37398
537.
Ansari MM, et al. Aminocellulose-grafted-polycaprolactone coated gelatin nanoparticles alleviate inflammation in rheumatoid arthritis: a combinational therapeutic approach. Carbohydr. Polym. 2021;258:117600.
Not in our library10.1016/j.carbpol.2020.117600
538.
Nanoparticle-assembled bioadhesive coacervate coating with prolonged gastrointestinal retention for inflammatory bowel disease therapy · 2021
No notice
539.
Yang C, et al. Natural-lipid nanoparticle-based therapeutic approach to deliver 6-shogaol and its metabolites M2 and M13 to the colon to treat ulcerative colitis. J. Control Release. 2020;323:293-310.
Not in our library10.1016/j.jconrel.2020.04.032
540.
Zhang J, et al. Engineering non-covalently assembled protein nanoparticles for long-acting gouty arthritis therapy. J. Mater. Chem. B. 2021;9:9923-9931.
Not in our library10.1039/d1tb01760h
541.
Wang Q, et al. Inhibition of atherosclerosis progression by modular micelles. J. Control Release. 2023;354:294-304.
Not in our library10.1016/j.jconrel.2023.01.020
542.
Dubreil C, et al. Tolerogenic iron oxide nanoparticles in type 1 diabetes: biodistribution and pharmacokinetics studies in nonobese diabetic mice. Small. 2018;14:e1802053.
Not in our library10.1002/smll.201802053
543.
Ungaro R, et al. Ulcerative colitis. Lancet. 2017;389:1756-1770.
Not in our library10.1016/s0140-6736(16)32126-2
544.
Bauché D, et al. LAG3+ regulatory T cells restrain interleukin-23-Producing CX3CR1+ Gut-resident macrophages during group 3 innate lymphoid cell-driven colitis. Immunity. 2018;49:342-352.e345.
Not in our library10.1016/j.immuni.2018.07.007
545.
Matondo A, Kim SS. Targeted-mitochondria antioxidants therapeutic implications in inflammatory bowel disease. J. Drug Target. 2017;26:1-8.
Not in our library10.1080/1061186x.2017.1339196
546.
Chen Y, et al. Orally deliverable sequence-targeted astaxanthin nanoparticles for colitis alleviation. Biomaterials. 2023;293:121976.
Not in our library10.1016/j.biomaterials.2022.121976
547.
Xiao B, et al. TNFα gene silencing mediated by orally targeted nanoparticles combined with interleukin-22 for synergistic combination therapy of ulcerative colitis. J. Control Release. 2018;287:235-246.
Not in our library10.1016/j.jconrel.2018.08.021
548.
Xu J, et al. A multifunctional composite hydrogel as an intrinsic and extrinsic coregulator for enhanced therapeutic efficacy for psoriasis. J. Nanobiotechnol. 2022;20:155.
Not in our library10.1186/s12951-022-01368-y
549.
Wang Y, et al. Chitosan/hyaluronan nanogels co-delivering methotrexate and 5-aminolevulinic acid: a combined chemo-photodynamic therapy for psoriasis. Carbohydr. Polym. 2022;277:118819.
Not in our library10.1016/j.carbpol.2021.118819
550.
Furtado D, et al. Overcoming the Blood–Brain Barrier: the role of nanomaterials in treating neurological diseases. Adv. Mater. 2018;30:e1801362.
Not in our library10.1002/adma.201801362
551.
Wang B, et al. Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy. Bioact. Mater. 2022;16:232-248.
Not in our library10.1016/j.bioactmat.2022.02.026
552.
Parvez S, et al. Dodging blood brain barrier with “nano” warriors: Novel strategy against ischemic stroke. Theranostics. 2022;12:689-719.
Not in our library10.7150/thno.64806
553.
Cyclosporine A loaded brain targeting nanoparticle to treat cerebral ischemia/reperfusion injury in mice · 2022
Not checked
554.
Mu Q, et al. Ligustrazine nanoparticle hitchhiking on neutrophils for enhanced therapy of cerebral ischemia‐reperfusion injury. Adv. Sci. 2023;10:e2301348.
Not in our library10.1002/advs.202301348
555.
Guo X, et al. Multifunctional selenium quantum dots for the treatment of Alzheimer’s disease by reducing Aβ-neurotoxicity and oxidative stress and alleviate neuroinflammation. ACS Appl. Mater. Interfaces. 2021;13:30261-30273.
Not in our library10.1021/acsami.1c00690
556.
Yan Y, et al. Topical cationic hairy particles targeting cell free DNA in dermis enhance treatment of psoriasis. Biomaterials. 2021;276:121027.
Not in our library10.1016/j.biomaterials.2021.121027
557.
Liang H, et al. Topical nanoparticles interfering with the DNA-LL37 complex to alleviate psoriatic inflammation in mice and monkeys. Sci. Adv. 2020;6:eabb5274.
Not in our library10.1126/sciadv.abb5274
558.
Wu C, et al. Advances in treatment strategies based on scavenging reactive oxygen species of nanoparticles for atherosclerosis. J. Nanobiotechnol. 2023;21:271.
Not in our library10.1186/s12951-023-02058-z
559.
Gao Y, et al. Reduction of reactive oxygen species accumulation using gadolinium-doped ceria for the alleviation of atherosclerosis. ACS Appl. Mater. Interfaces. 2023;15:10414-10425.
Not in our library10.1021/acsami.2c20492
560.
Yang B, Shi J. Ferrihydrite nanoparticles alleviate rheumatoid arthritis by nanocatalytic antioxidation and oxygenation. Nano Lett. 2023;23:8355-8362.
Not in our library10.1021/acs.nanolett.3c02743
561.
Qiang R, et al. Carbon quantum dots derived from herbal medicine as therapeutic nanoagents for rheumatoid arthritis with ultrahigh lubrication and anti-inflammation. ACS Appl. Mater. Interfaces. 2023;15:38653-38664.
Not in our library10.1021/acsami.3c06188
562.
Liu X, et al. CaP-based anti-inflammatory HIF-1α siRNA-encapsulating nanoparticle for rheumatoid arthritis therapy. J. Control Release. 2022;343:314-325.
Not in our library10.1016/j.jconrel.2022.01.029
563.
Ye C, et al. Oxytocin nanogels inhibit innate inflammatory response for early intervention in Alzheimer’s disease. ACS Appl. Mater. Interfaces. 2022;14:21822-21835.
Not in our library10.1021/acsami.2c00007
564.
Asadi S, et al. Beneficial effects of nano‐curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double‐blind, placebo‐controlled clinical trial. Phytother. Res. 2019;34:896-903.
Not in our library10.1002/ptr.6571
565.
Lu L, et al. Targeted immunomodulation of inflammatory monocytes across the blood-brain barrier by curcumin-loaded nanoparticles delays the progression of experimental autoimmune encephalomyelitis. Biomaterials. 2020;245:119987.
Not in our library10.1016/j.biomaterials.2020.119987
566.
Yunna C, Mengru H, Lei W, Weidong C. Macrophage M1/M2 polarization. Eur. J. Pharm. Biopharm. 2020;877:173090.
Not in our library10.1016/j.ejphar.2020.173090
567.
Mantovani A, et al. Macrophage plasticity and polarization in tissue repair and remodelling. J. Pathol. 2012;229:176-185.
Not in our library10.1002/path.4133
568.
Macrophage Polarization and Its Role in Liver Disease · 2021
No notice
569.
Qian F, et al. The transcription factor PU.1 promotes alternative macrophage polarization and asthmatic airway inflammation. J. Mol. Cell Biol. 2015;7:557-567.
Not in our library10.1093/jmcb/mjv042
570.
Lee YG, et al. Recruited alveolar macrophages, in response to airway epithelial–derived monocyte chemoattractant protein 1/CCL2, regulate airway inflammation and remodeling in allergic asthma. Am. J. Respir. Cell Mol. Biol. 2015;52:772-784.
Not in our library10.1165/rcmb.2014-0255oc
571.
Zhao J, et al. M1/M2 re-polarization of kaempferol biomimetic NPs in anti-inflammatory therapy of atherosclerosis. J. Control Release. 2023;353:1068-1083.
Not in our library10.1016/j.jconrel.2022.12.041
572.
Sun L, et al. Nano‐enabled reposition of proton pump inhibitors for TLR inhibition: toward a new targeted nanotherapy for acute lung injury. Adv. Sci. 2021;9:e2104051.
Not in our library10.1002/advs.202104051
573.
Wang L, et al. Administration route governs the therapeutic efficacy, biodistribution and macrophage targeting of anti-inflammatory nanoparticles in the lung. J. Nanobiotechnol. 2021;19:56.
Not in our library10.1186/s12951-021-00803-w
574.
Prasad S, et al. Tolerogenic Ag-PLG nanoparticles induce tregs to suppress activated diabetogenic CD4 and CD8 T cells. J. Autoimmun. 2018;89:112-124.
Not in our library10.1016/j.jaut.2017.12.010
575.
Kuo R, Saito E, Miller SD, Shea LD. Peptide-conjugated nanoparticles reduce positive co-stimulatory expression and T cell activity to induce tolerance. Mol. Ther. 2017;25:1676-1685.
Not in our library10.1016/j.ymthe.2017.03.032
576.
An E-K, et al. Immunosuppressive nanoparticles containing recombinant PD-L1 and methotrexate alleviate multi-organ inflammation. Biomaterials. 2023;301:122233.
Not in our library10.1016/j.biomaterials.2023.122233
577.
Guo Q, et al. Engineered PD-1/TIGIT dual-activating cell-membrane nanoparticles with dexamethasone act synergistically to shape the effector T cell/Treg balance and alleviate systemic lupus erythematosus. Biomaterials. 2022;285:121517.
Not in our library10.1016/j.biomaterials.2022.121517
578.
Yang J, Sundrud MS, Skepner J, Yamagata T. Targeting Th17 cells in autoimmune diseases. Trends Pharmacol. Sci. 2014;35:493-500.
Not in our library10.1016/j.tips.2014.07.006
579.
Moser T, et al. The role of TH17 cells in multiple sclerosis: therapeutic implications. Autoimmun. Rev. 2020;19:102647.
Not in our library10.1016/j.autrev.2020.102647
580.
Gammon JM, et al. Controlled delivery of a metabolic modulator promotes regulatory T cells and restrains autoimmunity. J. Control Release. 2015;210:169-178.
Not in our library10.1016/j.jconrel.2015.05.277
581.
Qiao H, et al. Immune-regulating strategy against rheumatoid arthritis by inducing tolerogenic dendritic cells with modified zinc peroxide nanoparticles. J. Nanobiotechnol. 2022;20:323.
Not in our library10.1186/s12951-022-01536-0
582.
Rahiman N, et al. Recent advancements in nanoparticle-mediated approaches for restoration of multiple sclerosis. J. Control Release. 2022;343:620-644.
Not in our library10.1016/j.jconrel.2022.02.009
583.
Wan H, Du H, Wang F, Dai H. Molecular imaging in the second near‐infrared window. Adv. Funct. Mater. 2019;29:1900566.
Not in our library10.1002/adfm.201900566
584.
Xu W, Wang D, Tang BZ. NIR‐II AIEgens: a win–win integration towards bioapplications. Angew. Chem. Int. Ed. 2020;60:7476-7487.
Not in our library10.1002/anie.202005899
585.
Zeng Z, et al. A biomarker‐responsive nanosystem with colon‐targeted delivery for ulcerative colitis’s detection and treatment with optoacoustic/NIR‐II fluorescence imaging. Adv. Healthc. 2022;11:e2201544.
Not in our library10.1002/adhm.202201544
586.
Yang Y, et al. Semiconducting polymer nanoparticles as theranostic system for near-infrared-II fluorescence imaging and photothermal therapy under safe laser fluence. ACS Nano. 2020;14:2509-2521.
Not in our library10.1021/acsnano.0c00043
587.
Guo Y, et al. In vivo NIR‐II fluorescence lifetime imaging of whole‐body vascular using high quantum yield lanthanide‐doped nanoparticles. Small. 2023;19:e2300392.
Not in our library10.1002/smll.202300392
588.
Sun C, Lee JSH, Zhang M. Magnetic nanoparticles in MR imaging and drug delivery. Adv. Drug Deliv. Rev. 2008;60:1252-1265.
Not in our library10.1016/j.addr.2008.03.018
589.
Poon C, et al. Hybrid, metal oxide-peptide amphiphile micelles for molecular magnetic resonance imaging of atherosclerosis. J. Nanobiotechnol. 2018;16:92.
Not in our library10.1186/s12951-018-0420-8
590.
Naha PC, et al. Dextran-coated cerium oxide nanoparticles: a computed tomography contrast agent for imaging the gastrointestinal tract and inflammatory Bowel disease. ACS Nano. 2020;14:10187-10197.
Not in our library10.1021/acsnano.0c03457
591.
Pang X, et al. A photoelectrochemical biosensor for fibroblast-like synoviocyte cell using visible light-activated NCQDs sensitized-ZnO/CH 3 NH 3 PbI 3 heterojunction. Biosens. Bioelectron. 2016;77:330-338.
Not in our library10.1016/j.bios.2015.09.047
592.
Liu S, Shen Z, Deng L, Liu G. Smartphone assisted portable biochip for non-invasive simultaneous monitoring of glucose and insulin towards precise diagnosis of prediabetes/diabetes. Biosens. Bioelectron. 2022;209:114251.
Not in our library10.1016/j.bios.2022.114251
593.
Gold nanoparticles and gold nanorods in the landscape of cancer therapy · 2023
No notice
594.
Tisch U, et al. Detection of Alzheimer’s and Parkinson’s disease from exhaled breath using nanomaterial-based sensors. Nanomedicine. 2013;8:43-56.
Not in our library10.2217/nnm.12.105
595.
Li X, et al. Surface chemistry governs the sub-organ transfer, clearance and toxicity of functional gold nanoparticles in the liver and kidney. J. Nanobiotechnol. 2020;18:45.
Not in our library10.1186/s12951-020-00599-1
596.
Belal R, Gad A. Zinc oxide nanoparticles induce oxidative stress, genotoxicity, and apoptosis in the hemocytes of Bombyx mori larvae. Sci. Rep. 2023;13:3520.
Not in our library10.1038/s41598-023-30444-y
597.
Nanoparticles‐induced potential toxicity on human health: Applications, toxicity mechanisms, and evaluation models · 2023
No notice
598.
Xiong P, et al. Cytotoxicity of metal‐based nanoparticles: from mechanisms and methods of evaluation to pathological manifestations. Adv. Sci. 2022;9:e2106049.
Not in our library10.1002/advs.202106049
599.
Buchman JT, Hudson-Smith NV, Landy KM, Haynes CL. Understanding nanoparticle toxicity mechanisms to inform redesign strategies to reduce environmental impact. Acc. Chem. Res. 2019;52:1632-1642.
Not in our library10.1021/acs.accounts.9b00053
600.
Bhargava A, et al. Pre-coating of protein modulate patterns of corona formation, physiological stability and cytotoxicity of silver nanoparticles. Sci. Total Environ. 2021;772:144797.
Not in our library10.1016/j.scitotenv.2020.144797
601.
Sereemaspun A, Rojanathanes R, Wiwanitkit V. Effect of gold nanoparticle on renal cell: an implication for exposure risk. Ren. Fail. 2009;30:323-325.
Not in our library10.1080/08860220701860914
602.
Lee P, et al. Biokinetics of subacutely co-inhaled same size gold and silver nanoparticles. Part. Fibre Toxicol. 2023;20:9.
Not in our library10.1186/s12989-023-00515-z
603.
Kreyling WG, et al. Age-dependent rat lung deposition patterns of inhaled 20 nanometer gold nanoparticles and their quantitative biokinetics in adult rats. ACS Nano. 2018;12:7771-7790.
Not in our library10.1021/acsnano.8b01826
604.
Peng C, Yu M, Zheng J. In situ ligand-directed growth of gold nanoparticles in biological tissues. Nano Lett. 2019;20:1378-1382.
Not in our library10.1021/acs.nanolett.9b04911
605.
Antony JJ, Sivalingam P, Chen B. Toxicological effects of silver nanoparticles. Environ. Toxicol. Pharmacol. 2015;40:729-732.
Not in our library10.1016/j.etap.2015.09.003
606.
Yoisungnern T, et al. Internalization of silver nanoparticles into mouse spermatozoa results in poor fertilization and compromised embryo development. Sci. Rep. 2015;5:11170.
Not in our library10.1038/srep11170
607.
Asbestos, carbon nanotubes and the pleural mesothelium: a review and the hypothesis regarding the role of long fibre retention in the parietal pleura, inflammation and mesothelioma · 2010
No notice
608.
STAT1-dependent and -independent pulmonary allergic and fibrogenic responses in mice after exposure to tangled versus rod-like multi-walled carbon nanotubes · 2017
Not checked
609.
Urankar RN, et al. Expansion of cardiac ischemia/reperfusion injury after instillation of three forms of multi-walled carbon nanotubes. Part. Fibre Toxicol. 2012;9:38.
Not in our library10.1186/1743-8977-9-38
610.
Young TL, et al. Pulmonary delivery of the broad-spectrum matrix metalloproteinase inhibitor marimastat diminishes multiwalled carbon nanotube-induced circulating bioactivity without reducing pulmonary inflammation. Part. Fibre Toxicol. 2021;18:34.
Not in our library10.1186/s12989-021-00427-w
611.
Meller S, et al. Allergic sensitization to pegylated interferon‐α results in drug eruptions. Allergy. 2015;70:775-783.
Not in our library10.1111/all.12618
612.
Wang M, et al. Oligomer nanoparticle release from polylactic acid plastics catalysed by gut enzymes triggers acute inflammation. Nat. Nanotechnol. 2023;18:403-411.
Not in our library10.1038/s41565-023-01329-y
613.
Campbell F, et al. Directing nanoparticle biodistribution through evasion and exploitation of Stab2-dependent nanoparticle uptake. ACS Nano. 2018;12:2138-2150.
Not in our library10.1021/acsnano.7b06995
614.
Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB · 2021
Corrected
615.
Elsaesser A, Howard CV. Toxicology of nanoparticles. Adv. Drug Deliv. Rev. 2012;64:129-137.
Not in our library10.1016/j.addr.2011.09.001
616.
Ginzburg VV, Balijepalli S. Modeling the thermodynamics of the interaction of nanoparticles with cell membranes. Nano Lett. 2007;7:3716-3722.
Not in our library10.1021/nl072053l
617.
Uppal S, Italiya KS, Chitkara D, Mittal A. Nanoparticulate-based drug delivery systems for small molecule anti-diabetic drugs: An emerging paradigm for effective therapy. Acta Biomater. 2018;81:20-42.
Not in our library10.1016/j.actbio.2018.09.049
618.
Yacobi NR, et al. Mechanisms of alveolar epithelial translocation of a defined population of nanoparticles. Am. J. Respir. Cell Mol. Biol. 2010;42:604-614.
Not in our library10.1165/rcmb.2009-0138oc
619.
Toxicity of Nanoparticles in Biomedical Application: Nanotoxicology · 2021
No notice
620.
Liu Y, et al. Toxicity of manufactured nanomaterials. Particuology. 2022;69:31-48.
Not in our library10.1016/j.partic.2021.11.007
621.
Mohammadpour R, et al. Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications. Adv. Drug Deliv. Rev. 2019;144:112-132.
Not in our library10.1016/j.addr.2019.07.006
622.
Trotta F, et al. Integration of cyclodextrins and associated toxicities: a roadmap for high quality biomedical applications. Carbohydr. Polym. 2022;295:119880.
Not in our library10.1016/j.carbpol.2022.119880
623.
Labouta HI, Asgarian N, Rinker K, Cramb DT. Meta-analysis of nanoparticle cytotoxicity via data-mining the literature. ACS Nano. 2019;13:1583-1594.
Not in our library10.1021/acsnano.8b07562
624.
Roshanzadeh A, et al. Surface charge-dependent cytotoxicity of plastic nanoparticles in alveolar cells under cyclic stretches. Nano Lett. 2020;20:7168-7176.
Not in our library10.1021/acs.nanolett.0c02463
625.
Schaeublin NM, et al. Surface charge of gold nanoparticles mediates mechanism of toxicity. Nanoscale. 2011;3:410-420,.
Not in our library10.1039/c0nr00478b
626.
Yu M, Xu J, Zheng J. Renal clearable luminescent gold nanoparticles: from the bench to the clinic. Angew. Chem. Int. Ed. 2019;58:4112-4128.
Not in our library10.1002/anie.201807847
627.
Ge X, et al. Lanthanide (Gd3+ and Yb3+) functionalized gold nanoparticles for in vivo imaging and therapy. Biomaterials. 2016;108:35-43.
Not in our library10.1016/j.biomaterials.2016.08.051
628.
Challenges in Development of Nanoparticle-Based Therapeutics · 2012
No notice
629.
Ejazi SA, Louisthelmy R, Maisel K. Mechanisms of nanoparticle transport across intestinal tissue: an oral delivery perspective. ACS Nano. 2023;17:13044-13061.
Not in our library10.1021/acsnano.3c02403
630.
Beatty PH, Lewis JD. Cowpea mosaic virus nanoparticles for cancer imaging and therapy. Adv. Drug Deliv. Rev. 2019;145:130-144.
Not in our library10.1016/j.addr.2019.04.005
631.
Poon W, et al. Elimination pathways of nanoparticles. ACS Nano. 2019;13:5785-5798.
Not in our library10.1021/acsnano.9b01383
632.
Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 2012;64:557-570.
Not in our library10.1016/j.addr.2011.12.009
633.
He W, Zhang Z, Sha X. Nanoparticles-mediated emerging approaches for effective treatment of ischemic stroke. Biomaterials. 2021;277:121111.
Not in our library10.1016/j.biomaterials.2021.121111
634.
Falconer JL, Grainger DW. In vivo comparisons of silver nanoparticle and silver ion transport after intranasal delivery in mice. J. Control Release. 2018;269:1-9.
Not in our library10.1016/j.jconrel.2017.10.018
635.
Wen J, et al. Synthesized nanoparticles, biomimetic nanoparticles and extracellular vesicles for treatment of autoimmune disease: comparison and prospect. Pharmacol. Res. 2021;172:105833.
Not in our library10.1016/j.phrs.2021.105833
636.
Paunovska K, et al. Using large datasets to understand nanotechnology. Adv. Mater. 2019;31:e1902798.
Not in our library10.1002/adma.201902798
637.
Progress and challenges towards targeted delivery of cancer therapeutics · 2018
No notice
638.
Gao H, et al. Ligand modified nanoparticles increases cell uptake, alters endocytosis and elevates glioma distribution and internalization. Sci. Rep. 2013;3:2534.
Not in our library10.1038/srep02534
639.
Ang MJY, et al. Deciphering nanoparticle trafficking into glioblastomas uncovers an augmented antitumor effect of metronomic chemotherapy. Adv. Mater. 2021;34:e2106194.
Not in our library10.1002/adma.202106194
640.
Wang C, et al. Liquid core nanoparticle with high deformability enables efficient penetration across biological barriers. Adv. Healthc. 2022;12:e2201889.
Not in our library10.1002/adhm.202201889
641.
Zhang Z, et al. Mechanistic study of silica nanoparticles on the size-dependent retinal toxicity in vitro and in vivo. J. Nanobiotechnol. 2022;20:146.
Not in our library10.1186/s12951-022-01326-8
642.
Costimulatory Molecules on Immunogenic Versus Tolerogenic Human Dendritic Cells · 2013
No notice
643.
Narasimhan B, Goodman JT, Vela Ramirez JE. Rational design of targeted next-generation carriers for drug and vaccine delivery. Annu Rev. Biomed. Eng. 2016;18:25-49.
Not in our library10.1146/annurev-bioeng-082615-030519
644.
Tokatlian T, et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science. 2019;363:649-654.
Not in our library10.1126/science.aat9120
645.
Verma V, Ryan KM, Padrela L. Production and isolation of pharmaceutical drug nanoparticles. Int. J. Pharm. 2021;603:120708.
Not in our library10.1016/j.ijpharm.2021.120708
646.
Ruan S, et al. Mechanical force-induced dispersion of starch nanoparticles and nanoemulsion: Size control, dispersion behaviour, and emulsified stability. Carbohydr. Polym. 2022;275:118711.
Not in our library10.1016/j.carbpol.2021.118711
647.
Chen X, et al. Plant-based nanoparticles prepared from proteins and phospholipids consisting of a core–multilayer-shell structure: fabrication, stability, and foamability. J. Agric. Food Chem. 2019;67:6574-6584.
Not in our library10.1021/acs.jafc.9b02028
648.
Surnar B, et al. Orally administrable therapeutic synthetic nanoparticle for Zika virus. ACS Nano. 2019;13:11034-11048.
Not in our library10.1021/acsnano.9b02807
649.
Caparco AA, et al. Delivery of nematicides using TMGMV-derived spherical nanoparticles. Nano Lett. 2023;23:5785-5793.
Not in our library10.1021/acs.nanolett.3c01684
650.
Huynh NT, Passirani C, Saulnier P, Benoit JP. Lipid nanocapsules: a new platform for nanomedicine. Int. J. Pharm. 2009;379:201-209.
Not in our library10.1016/j.ijpharm.2009.04.026
651.
Awaad A, Elkady EF, El-Mahdy SM. Time-dependent biodistribution profiles and reaction of polyethylene glycol-coated iron oxide nanoclusters in the spleen after intravenous injection in the mice. Acta Histochem. 2022;124:151907.
Not in our library10.1016/j.acthis.2022.151907
652.
Uptake, distribution, clearance, and toxicity of iron oxide nanoparticles with different sizes and coatings · 2018
No notice
653.
Tian L, et al. Melanin-like nanoparticles: advances in surface modification and tumour photothermal therapy. J. Nanobiotechnol. 2022;20:485.
Not in our library10.1186/s12951-022-01698-x
654.
Kang H, et al. Stabilization of silver and gold nanoparticles: preservation and improvement of plasmonic functionalities. Chem. Rev. 2018;119:664-699.
Not in our library10.1021/acs.chemrev.8b00341
655.
Grzelczak M, Pérez-Juste J, Mulvaney P, Liz-Marzán LM. Shape control in gold nanoparticle synthesis. Chem. Soc. Rev. 2008;37:1783-1791.
Not in our library10.1039/b711490g
656.
Yang L, Wang H, Fang Y, Li Z. Polarization state of light scattered from quantum plasmonic dimer antennas. ACS Nano. 2015;10:1580-1588.
Not in our library10.1021/acsnano.5b07223
657.
Gillich T, et al. PEG-stabilized core–shell nanoparticles: impact of linear versus dendritic polymer shell architecture on colloidal properties and the reversibility of temperature-induced aggregation. ACS Nano. 2012;7:316-329.
Not in our library10.1021/nn304045q
658.
Höller RPM, et al. Protein-assisted assembly of modular 3D plasmonic raspberry-like core/satellite nanoclusters: correlation of structure and optical properties. ACS Nano. 2016;10:5740-5750.
Not in our library10.1021/acsnano.5b07533
659.
Silvestri T, et al. Investigating the effect of surface hydrophilicity on the destiny of PLGA-poloxamer nanoparticles in an in vivo animal model. Int. J. Mol. Sci. 2023;24:14523.
Not in our library10.3390/ijms241914523
660.
Mohammed DM, et al. Effect of nano-encapsulated food flavorings on streptozotocin-induced diabetic rats. Food Funct. 2023;14:8814-8828.
Not in our library10.1039/d3fo01299a
661.
Shen Z, et al. Lipid nanoparticle‐mediated delivery of IL‐21‐encoding mRNA induces viral clearance in mouse models of hepatitis B virus persistence. J. Med. Virol. 2023;95:e29062.
Not in our library10.1002/jmv.29062
662.
Srinivasan SY, et al. Arrhythmic effects evaluated on Caenorhabditis elegans: the case of polypyrrole nanoparticles. ACS Nano. 2023;17:17273-17284.
Not in our library10.1021/acsnano.3c05245
663.
Progressing nanotechnology to improve targeted cancer treatment: overcoming hurdles in its clinical implementation · 2023
No notice
664.
Huang Y, et al. Reactive oxygen species-sensitive biodegradable mesoporous silica nanoparticles harboring TheraVac elicit tumor-specific immunity for colon tumor treatment. ACS Nano. 2023;17:19740-19752.
Not in our library10.1021/acsnano.3c03195
665.
Ko MJ, et al. Magnetic nanoparticles for ferroptosis cancer therapy with diagnostic imaging. Bioact. Mater. 2024;32:66-97.
Not in our library10.1016/j.bioactmat.2023.09.015
666.
Wheatley AK, Kent SJ. Strength in diversity: widening B cell recruitment for broader vaccine protection. Immunity. 2023;56:2182-2184.
Not in our library10.1016/j.immuni.2023.09.009
667.
Widge AT, et al. An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults. Sci. Transl. Med. 2023;15:eade4790.
Not in our library10.1126/scitranslmed.ade4790
668.
Antoine TE, et al. Intravaginal zinc oxide tetrapod nanoparticles as novel immunoprotective agents against genital herpes. J. Immunol. 2016;196:4566-4575.
Not in our library10.4049/jimmunol.1502373
669.
Liu L, et al. Single-cell diagnosis of cancer drug resistance through the differential endocytosis of nanoparticles between drug-resistant and drug-sensitive cancer cells. ACS Nano. 2023;17:19372-19386.
Not in our library10.1021/acsnano.3c07030
670.
Siraj EA, Yayehrad AT, Belete A. How combined macrolide nanomaterials are effective against resistant pathogens? A comprehensive review of the literature. Int. J. Nanomed. 2023;18:5289-5307.
Not in our library10.2147/ijn.s418588
671.
Komalla V, et al. Advances in soft mist inhalers. Expert Opin. Drug Deliv. 2023;20:1055-1070.
Not in our library10.1080/17425247.2023.2231850
672.
Vora LK, et al. Long-acting microneedle formulations. Adv. Drug Deliv. Rev. 2023;201:115055.
Not in our library10.1016/j.addr.2023.115055
673.
van der Valk FM, et al. Prednisolone-containing liposomes accumulate in human atherosclerotic macrophages upon intravenous administration. Nanomedicine. 2015;11:1039-1046.
Not in our library10.1016/j.nano.2015.02.021
674.
Bentzon JF, Falk E. Atherosclerotic lesions in mouse and man: is it the same disease? Curr. Opin. Lipidol. 2010;21:434-440.
Not in our library10.1097/mol.0b013e32833ded6a
675.
Chen W, et al. Macrophage-targeted nanomedicine for the diagnosis and treatment of atherosclerosis. Nat. Rev. Cardiol. 2021;19:228-249.
Not in our library10.1038/s41569-021-00629-x
676.
Metselaar JM, et al. Intravenous pegylated liposomal prednisolone outperforms intramuscular methylprednisolone in treating rheumatoid arthritis flares: a randomized controlled clinical trial. J. Control Release. 2022;341:548-554.
Not in our library10.1016/j.jconrel.2021.12.007
677.
Han Y, Huang S. Nanomedicine is more than a supporting role in rheumatoid arthritis therapy. J. Control Release. 2023;356:142-161.
Not in our library10.1016/j.jconrel.2023.02.035
678.
Owens TC, Anton N, Attia MF. CT and X-ray contrast agents: current clinical challenges and the future of contrast. Acta Biomater. 2023;171:19-36.
Not in our library10.1016/j.actbio.2023.09.027
679.
Ma J-C, et al. Exploring the translational potential of PLGA nanoparticles for intra-articular rapamycin delivery in osteoarthritis therapy. J. Nanobiotechnol. 2023;21:361.
Not in our library10.1186/s12951-023-02118-4
680.
Carvalho SG, et al. Multifunctional systems based on nano-in-microparticles as strategies for drug delivery: advances, challenges, and future perspectives. Expert Opin. Drug Deliv. 2023;20:1231-1249.
Not in our library10.1080/17425247.2023.2263360
681.
Liu L, Tang H, Wang Y. Nanotechnology-boosted biomaterials for osteoarthritis treatment: current status and future perspectives. Int. J. Nanomed. 2023;18:4969-4983.
Not in our library10.2147/ijn.s423737
682.
Li B, et al. Powering mesoporous silica nanoparticles into bioactive nanoplatforms for antibacterial therapies: strategies and challenges. J. Nanobiotechnol. 2023;21:325.
Not in our library10.1186/s12951-023-02093-w
683.
He H, et al. Survey of clinical translation of cancer nanomedicines—lessons learned from successes and failures. Acc. Chem. Res. 2019;52:2445-2461.
Not in our library10.1021/acs.accounts.9b00228
684.
Younis MA, et al. Clinical translation of nanomedicines: challenges, opportunities, and keys. Adv. Drug Deliv. Rev. 2022;181:114083.
Not in our library10.1016/j.addr.2021.114083
685.
Colombo S, et al. Transforming nanomedicine manufacturing toward Quality by Design and microfluidics. Adv. Drug Deliv. Rev. 2018;128:115-131.
Not in our library10.1016/j.addr.2018.04.004
686.
Jain K, et al. 3D Printing in development of nanomedicines. Nanomaterials. 2021;11:420-443.
Not in our library10.3390/nano11020420
687.
Wang Y, et al. Recent advances of nanomedicine-based strategies in diabetes and complications management: Diagnostics, monitoring, and therapeutics. J. Control Release. 2021;330:618-640.
Not in our library10.1016/j.jconrel.2021.01.002
688.
Duggan S. Caplacizumab: first global approval. Drugs. 2018;78:1639-1642.
Not in our library10.1007/s40265-018-0989-0
689.
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics · 2017
No notice
690.
McMahon C, et al. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. Nat. Struct. Mol. Biol. 2018;25:289-296.
Not in our library10.1038/s41594-018-0028-6
691.
Nanomedicine: Principles, Properties, and Regulatory Issues · 2018
No notice
692.
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer · 2023
No notice
693.
Hao Y, et al. Lipid‐based nanoparticles as drug delivery systems for cancer immunotherapy. MedComm. 2023;4:e339.
Not in our library10.1002/mco2.339
694.
Xu X, et al. Use of a liver-targeting immune-tolerogenic mRNA lipid nanoparticle platform to treat peanut-induced anaphylaxis by single- and multiple-epitope nucleotide sequence delivery. ACS Nano. 2023;17:4942-4957.
Not in our library10.1021/acsnano.2c12420
695.
Cao W, Xia T. mRNA lipid nanoparticles induce immune tolerance to treat human diseases. Med. Rev. 2023;3:180-183.
Not in our library10.1515/mr-2023-0008
696.
Flemming A. mRNA vaccine shows promise in autoimmunity. Nat. Rev. Immunol. 2021;21:72-72.
Not in our library10.1038/s41577-021-00504-3
697.
Krienke C, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371:145-153.
Not in our library10.1126/science.aay3638
698.
Conde J, Langer R, Rueff J. mRNA therapy at the convergence of genetics and nanomedicine. Nat. Nanotechnol. 2023;18:537-540.
Not in our library10.1038/s41565-023-01347-w
699.
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection · 2021
No notice
700.
Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus · 2019
No notice
701.
Song W-F, et al. Targeting to tumor-harbored bacteria for precision tumor therapy. ACS Nano. 2022;16:17402-17413.
Not in our library10.1021/acsnano.2c08555
702.
Wang Y, et al. Genetically engineered bacteria-mediated multi-functional nanoparticles for synergistic tumor-targeting therapy. Acta Biomater. 2022;150:337-352.
Not in our library10.1016/j.actbio.2022.07.056
703.
Du Y, et al. Drug-loaded nanoparticles conjugated with genetically engineered bacteria for cancer therapy. Biochem. Biophys. Res. Commun. 2022;606:29-34.
Not in our library10.1016/j.bbrc.2022.03.049
704.
Jiang F, et al. US/MR bimodal imaging-guided bio-targeting synergistic agent for tumor therapy. Int. J. Nanomed. 2022;17:2943-2960.
Not in our library10.2147/ijn.s363645
705.
Wang Y, et al. Dual mode imaging guided multi-functional bio-targeted oxygen production probes for tumor therapy. J. Nanobiotechnol. 2023;21:142.
Not in our library10.1186/s12951-023-01901-7
706.
Luo Z, Yi Z, Liu X. Surface engineering of lanthanide nanoparticles for oncotherapy. Acc. Chem. Res. 2023;56:425-439.
Not in our library10.1021/acs.accounts.2c00681
707.
Kingston BR, et al. Assessing micrometastases as a target for nanoparticles using 3D microscopy and machine learning. Proc. Natl Acad. Sci. USA. 2019;116:14937-14946.
Not in our library10.1073/pnas.1907646116
708.
Kaushal S, et al. Nano-biotechnology for bacteria identification and potent anti-bacterial properties: a review of current state of the art. Nanomaterials. 2023;13:2529.
Not in our library10.3390/nano13182529
709.
Yuwen L, Zhang S, Chao J. Recent advances in DNA nanotechnology-enabled biosensors for virus detection. Biosensors. 2023;13:822.
Not in our library10.3390/bios13080822
710.
Wei-Wen Hsiao W, et al. Nanomaterial-based biosensors for avian influenza virus: a new way forward. Talanta. 2023;265:124892.
Not in our library10.1016/j.talanta.2023.124892
711.
Song N, et al. Emerging nanotechnology for Alzheimer’s disease: from detection to treatment. J. Control Release. 2023;360:392-417.
Not in our library10.1016/j.jconrel.2023.07.004
712.
de Puig H, et al. Multiplexed rapid antigen tests developed using multicolored nanoparticles and cross-reactive antibody pairs: Implications for pandemic preparedness. Nano Today. 2022;47:101669.
Not in our library10.1016/j.nantod.2022.101669
713.
Chen AL, et al. Sandwich-type electrochemiluminescence immunosensor based on CDs@dSiO2 nanoparticles as nanoprobe and co-reactant. Biosensors. 2023;13:133.
Not in our library10.3390/bios13010133
714.
Huang H, et al. MXene-incorporated C60NPs and Au@Pt with dual-electric signal outputs for accurate detection of Mycobacterium tuberculosis ESAT-6 antigen. Biosens. Bioelectron. 2023;242:115734.
Not in our library10.1016/j.bios.2023.115734
715.
Mordini D, et al. Luminescent gold nanoclusters for bioimaging: increasing the ligand complexity. Nanomaterials. 2023;13:648.
Not in our library10.3390/nano13040648
716.
Han L, et al. Development of a dual mode UCNPs-MB biosensor in combination with PCR for sensitive detection of salmonella. Biosensors. 2023;13:475.
Not in our library10.3390/bios13040475
717.
Tang W-F, Tran A-T, Wang L-Y, Horng J-T. SARS-CoV-2 pandemics: an update of CRISPR in diagnosis and host–virus interaction studies. Biomed. J. 2023;46:100587.
Not in our library10.1016/j.bj.2023.02.007
718.
SHERLOCK and DETECTR: CRISPR-Cas Systems as Potential Rapid Diagnostic Tools for Emerging Infectious Diseases · 2021
Retracted
719.
Sima N, et al. SHERLOCK4HAT: a CRISPR-based tool kit for diagnosis of Human African Trypanosomiasis. EBioMedicine. 2022;85:104308.
Not in our library10.1016/j.ebiom.2022.104308
720.
Casati B, et al. Rapid, adaptable and sensitive Cas13-based COVID-19 diagnostics using ADESSO. Nat. Commun. 2022;13:3308.
Not in our library10.1038/s41467-022-30862-y
721.
Pena JM, et al. Real-time, multiplexed SHERLOCK for in vitro diagnostics. J. Mol. Diagn. 2023;25:428-437.
Not in our library10.1016/j.jmoldx.2023.03.009
722.
Allan-Blitz L-T, et al. Development of Cas13a-based assays for Neisseria gonorrhoeae detection and gyrase A determination. mSphere. 2023;8:e0041623.
Not in our library10.1128/msphere.00416-23
723.
Thakku SG, et al. Genome-wide tiled detection of circulating Mycobacterium tuberculosis cell-free DNA using Cas13. Nat. Commun. 2023;14:1803.
Not in our library10.1038/s41467-023-37183-8
724.
MacGregor SR, et al. Development of CRISPR/Cas13a-based assays for the diagnosis of Schistosomiasis. EBioMedicine. 2023;94:104730.
Not in our library10.1016/j.ebiom.2023.104730
725.
Li H, et al. Strategies to improve multi-enzyme compatibility and coordination in one-pot SHERLOCK. Anal. Chem. 2023;95:10522-10531.
Not in our library10.1021/acs.analchem.2c05032
726.
Yarnall MTN, et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat. Biotechnol. 2022;41:500-512.
Not in our library10.1038/s41587-022-01527-4
727.
El-Safty SA, Shenashen MA. Nanoscale dynamic chemical, biological sensor material designs for control monitoring and early detection of advanced diseases. Mater. Today Bio. 2020;5:100044.
Not in our library10.1016/j.mtbio.2020.100044
728.
Jhunjhunwala A, et al. In vivo photoacoustic monitoring of stem cell location and apoptosis with caspase-3-responsive nanosensors. ACS Nano. 2023;17:17931-17945.
Not in our library10.1021/acsnano.3c04161
729.
Harvey JD, et al. An in vivo nanosensor measures compartmental doxorubicin exposure. Nano Lett. 2019;19:4343-4354.
Not in our library10.1021/acs.nanolett.9b00956
730.
Zhang Y, et al. A nanometallic conductive composite-hydrogel core–shell microneedle skin patch for real-time monitoring of interstitial glucose levels. Nanoscale. 2023;15:16493-16500.
Not in our library10.1039/d3nr01245j
731.
Choi JH, et al. Combination of porous silk fibroin substrate and gold nanocracks as a novel SERS platform for a high-sensitivity biosensor. Biosensors. 2021;11:441.
Not in our library10.3390/bios11110441
732.
Chaparro CIP, et al. A promising approach: magnetic nanosystems for Alzheimer’s disease theranostics. Pharmaceutics. 2023;15:2316.
Not in our library10.3390/pharmaceutics15092316
733.
Fang L, et al. Hyperbranched polymer dots with strong absorption and high fluorescence quantum yield for in vivo NIR-II imaging. Nano Lett. 2023;23:8734-8742.
Not in our library10.1021/acs.nanolett.3c02751
734.
Zhang, Q. et al. Renal clearable magnetic nanoparticles for magnetic resonance imaging and guided therapy. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 10.1002/wnan.1929 (2023).
Not in our library10.1002/wnan.1929
735.
Liang R, et al. Multimodal imaging-guided strategy for developing 177Lu-labeled metal–organic framework nanomedicine with potential in cancer therapy. ACS Appl. Mater. Interfaces. 2023;15:45713-45724.
Not in our library10.1021/acsami.3c11098
736.
Rehan M, et al. Smart capsules for sensing and sampling the gut: status, challenges and prospects. Gut. 2024;73:186-202.
Not in our library10.1136/gutjnl-2023-329614
737.
Devnarain N, et al. Intrinsic stimuli‐responsive nanocarriers for smart drug delivery of antibacterial agents—An in‐depth review of the last two decades. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2020;13:e1664.
Not in our library10.1002/wnan.1664
738.
Gayet RV, et al. Creating CRISPR-responsive smart materials for diagnostics and programmable cargo release. Nat. Protoc. 2020;15:3030-3063.
Not in our library10.1038/s41596-020-0367-8
739.
Banaye Yazdipour A, et al. Predicting the toxicity of nanoparticles using artificial intelligence tools: a systematic review. Nanotoxicology. 2023;17:62-77.
Not in our library10.1080/17435390.2023.2186279
740.
Nuhn L. Artificial intelligence assists nanoparticles to enter solid tumours. Nat. Nanotechnol. 2023;18:550-551.
Not in our library10.1038/s41565-023-01382-7
741.
Subramanian NA, Palaniappan A. NanoTox: development of a parsimonious in silico model for toxicity assessment of metal-oxide nanoparticles using physicochemical features. ACS Omega. 2021;6:11729-11739.
Not in our library10.1021/acsomega.1c01076
742.
Yu F, et al. Deep exploration of random forest model boosts the interpretability of machine learning studies of complicated immune responses and lung burden of nanoparticles. Sci. Adv. 2021;7:eabf4130.
Not in our library10.1126/sciadv.abf4130
743.
Zhu M, et al. Machine-learning-assisted single-vessel analysis of nanoparticle permeability in tumour vasculatures. Nat. Nanotechnol. 2023;18:657-666.
Not in our library10.1038/s41565-023-01323-4
744.
Arber Raviv S, et al. Lung targeted liposomes for treating ARDS. J. Control Release. 2022;346:421-433.
Not in our library10.1016/j.jconrel.2022.03.028
745.
Richner JM, et al. Modified mRNA vaccines protect against Zika virus infection. Cell. 2017;168:1114-1125.e1110.
Not in our library10.1016/j.cell.2017.02.017
746.
Hou X, et al. Vitamin lipid nanoparticles enable adoptive macrophage transfer for the treatment of multidrug-resistant bacterial sepsis. Nat. Nanotechnol. 2020;15:41-46.
Not in our library10.1038/s41565-019-0600-1
747.
Xu Z, et al. Glycyrrhizic acid-lipid framework nanovehicle loading triptolide for combined immunochemotherapy. ACS Appl. Mater. Interfaces. 2023;15:41337-41350.
Not in our library10.1021/acsami.3c08003
748.
Xiang D-x, Chen Q, Pang L, Zheng C-l. Inhibitory effects of silver nanoparticles on H1N1 influenza A virus in vitro. J. Virol. Methods. 2011;178:137-142.
Not in our library10.1016/j.jviromet.2011.09.003
749.
Paul AM, et al. Delivery of antiviral small interfering RNA with gold nanoparticles inhibits dengue virus infection in vitro. J. Gen. Virol. 2014;95:1712-1722.
Not in our library10.1099/vir.0.066084-0
750.
Hang X, et al. Antiviral activity of cuprous oxide nanoparticles against Hepatitis C Virus in vitro. J. Virol. Methods. 2015;222:150-157.
Not in our library10.1016/j.jviromet.2015.06.010
751.
Howarth JR, et al. Interactions between multi-walled carbon nanotubes and plankton as detected by Raman spectroscopy. Chemosphere. 2022;295:133889.
Not in our library10.1016/j.chemosphere.2022.133889
752.
Deokar AR, et al. Graphene-based “hot plate” for the capture and destruction of the herpes simplex virus type 1. Bioconjug. Chem. 2017;28:1115-1122.
Not in our library10.1021/acs.bioconjchem.7b00030
753.
Bakry R, et al. Medicinal applications of fullerenes. Int J. Nanomed. 2007;2:639-649.
Not in our library
754.
Biswas R, et al. C60-β-cyclodextrin conjugates for enhanced nucleus delivery of doxorubicin. Nanoscale. 2022;14:4456-4462.
Not in our library10.1039/d2nr00777k
755.
Zmonarski SZ, Stojanowski J, Zmonarska J. Polymers with antiviral properties: a brief review. Polim. Med. 2021;50:79-82.
Not in our library10.17219/pim/131643
756.
Cao Z-T, et al. Protein binding affinity of polymeric nanoparticles as a direct indicator of their pharmacokinetics. ACS Nano. 2020;14:3563-3575.
Not in our library10.1021/acsnano.9b10015
757.
Kurtovic L, et al. Novel virus-like particle vaccine encoding the circumsporozoite protein of Plasmodium falciparum is immunogenic and induces functional antibody responses in mice. Front. Immunol. 2021;12:641421.
Not in our library10.3389/fimmu.2021.641421
758.
Engineered virus-like particles for efficient in vivo delivery of therapeutic proteins · 2022
No notice
759.
Zhang P, et al. Dual-sensitive antibacterial peptide nanoparticles prevent dental caries. Theranostics. 2022;12:4818-4833.
Not in our library10.7150/thno.73181
760.
Development of Spike Receptor-Binding Domain Nanoparticles as a Vaccine Candidate against SARS-CoV-2 Infection in Ferrets · 2021
Not checked
761.
Jochum S, et al. Clinical utility of Elecsys anti-SARS-CoV-2 S assay in COVID-19 vaccination: an exploratory analysis of the mRNA-1273 phase 1 trial. Front Immunol. 2021;12:798117.
Not in our library10.3389/fimmu.2021.798117
762.
Shabu A, Nishtala PS. Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review. Expert Rev. Vaccines. 2023;22:393-409.
Not in our library10.1080/14760584.2023.2209177
763.
Graña C, et al. Efficacy and safety of COVID-19 vaccines. Cochrane Database Syst. Rev. 2022;2023:Cd015477.
Not in our library10.1002/14651858.cd015477
764.
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial · 2021
No notice
765.
Martin-Orozco N, et al. Phase I randomized, observer-blinded, placebo-controlled study of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Sci. Rep. 2023;13:8557.
Not in our library10.1038/s41598-023-35662-y
766.
An Alphavirus -derived replicon RNA vaccine induces SARS-CoV-2 neutralizing antibody and T cell responses in mice and nonhuman primates · 2020
No notice
767.
A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques · 2021
Not checked
768.
Branche AR, et al. Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial. Nat. Med. 2023;29:2334-2346.
Not in our library10.1038/s41591-023-02503-4
769.
Johnston SC, et al. A SARS-CoV-2 spike ferritin nanoparticle vaccine is protective and promotes a strong immunological response in the cynomolgus macaque coronavirus disease 2019 (COVID-19) model. Vaccines. 2022;10:717.
Not in our library10.3390/vaccines10050717
770.
Joyce MG, et al. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity. Cell Rep. 2021;37:110143.
Not in our library10.1016/j.celrep.2021.110143
771.
Zhang H, et al. Adenovirus-mediated artificial MicroRNAs targeting matrix or nucleoprotein genes protect mice against lethal influenza virus challenge. Gene Ther. 2015;22:653-662.
Not in our library10.1038/gt.2015.31
772.
Song JY, et al. Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: a randomised, placebo-controlled, observer-blinded phase 1/2 trial. EClinicalMedicine. 2022;51:101569.
Not in our library10.1016/j.eclinm.2022.101569
773.
Gong J, Gujjula KR, Ntaimo L. An integrated chance constraints approach for optimal vaccination strategies under uncertainty for COVID-19. Socio-Econ. Plan. Sci. 2023;87:101547.
Not in our library10.1016/j.seps.2023.101547
774.
Shinde V, et al. Induction of cross-reactive hemagglutination inhibiting antibody and polyfunctional CD4+ T-cell responses by a recombinant matrix-M–adjuvanted hemagglutinin nanoparticle influenza vaccine. Clin. Infect. Dis. 2021;73:e4278-e4287.
Not in our library10.1093/cid/ciaa1673
775.
Toback S, et al. Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet. Respir. Med. 2022;10:167-179.
Not in our library10.1016/s2213-2600(21)00409-4
776.
Walls AC, et al. Distinct sensitivities to SARS-CoV-2 variants in vaccinated humans and mice. Cell Rep. 2022;40:111299.
Not in our library10.1016/j.celrep.2022.111299
777.
Pleguezuelos O, et al. Immunogenicity, safety, and efficacy of a standalone universal influenza vaccine, FLU-v, in healthy adults. Ann. Intern. Med. 2020;172:453-462,.
Not in our library10.7326/m19-0735
778.
Cohen JI, Fauci AS, Varmus H, Nabel GJ. Epstein-Barr virus: an important vaccine target for cancer prevention. Sci. Transl. Med. 2011;3:107fs107.
Not in our library10.1126/scitranslmed.3002878
779.
Epstein–barr virus vaccines · 2015
Corrected
780.
Kanekiyo M, et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell. 2015;162:1090-1100.
Not in our library10.1016/j.cell.2015.07.043
781.
Fries L, et al. Randomized, blinded, dose-ranging trial of an Ebola virus glycoprotein nanoparticle vaccine with matrix-M adjuvant in healthy adults. J. Infect. Dis. 2020;222:572-582.
Not in our library10.1093/infdis/jiz518
782.
Nebulization Therapy with Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for COVID-19 Pneumonia · 2022
No notice
783.
Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2 · 2022
No notice
784.
Lightner AL, et al. Bone marrow mesenchymal stem cell-derived extracellular vesicle infusion for the treatment of respiratory failure from COVID-19. Chest. 2023;164:1444-1453.
Not in our library10.1016/j.chest.2023.06.024
785.
Williams PE, Crauwels HM, Basstanie ED. Formulation and pharmacology of long-acting rilpivirine. Curr. Opin. HIV AIDS. 2015;10:233-238.
Not in our library10.1097/coh.0000000000000164
786.
Jackson AGA, et al. A compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin. Pharmacol. Ther. 2014;96:314-323.
Not in our library10.1038/clpt.2014.118
787.
Taléns-Visconti R, et al. Intranasal drug administration in Alzheimer-type dementia: towards clinical applications. Pharmaceutics. 2023;15:1399.
Not in our library10.3390/pharmaceutics15051399
788.
Gradishar WJ, et al. Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast. Cancer J. Clin. Oncol. 2009;27:3611-3619.
Not in our library10.1200/jco.2008.18.5397
789.
Farag AF, Hassabou NF. CD24-gold nanocomposite as promising and sensitive biomarker for cancer stem cells in salivary gland tumors. Nanomedicine. 2022;46:102598.
Not in our library10.1016/j.nano.2022.102598
790.
Hald Albertsen C, et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv. Drug Deliv. Rev. 2022;188:114416.
Not in our library10.1016/j.addr.2022.114416
791.
Díez-Pascual AM. Carbon-Based Nanomaterials. Int. J. Mol. Sci. 2021;22:7726.
Not in our library10.3390/ijms22147726
792.
Ferreira Soares DC, Domingues SC, Viana DB, Tebaldi ML. Polymer-hybrid nanoparticles: current advances in biomedical applications. Biomed. Pharmacother. 2020;131:110695.
Not in our library10.1016/j.biopha.2020.110695
793.
Shi J, Xiao Z, Kamaly N, Farokhzad OC. Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation. Acc. Chem. Res. 2011;44:1123-1134.
Not in our library10.1021/ar200054n
794.
Engineering exosomes for targeted drug delivery · 2021
No notice
795.
Vallhov H, et al. Adjuvant properties of mesoporous silica particles tune the development of effector T cells. Small. 2012;8:2116-2124.
Not in our library10.1002/smll.201102620
796.
Vallhov H, et al. Mesoporous silica particles induce size dependent effects on human dendritic cells. Nano Lett. 2007;7:3576-3582.
Not in our library10.1021/nl0714785
797.
Singh A. Eliciting B cell immunity against infectious diseases using nanovaccines. Nat. Nanotechnol. 2020;16:16-24.
Not in our library10.1038/s41565-020-00790-3
798.
Immunological properties of gold nanoparticles · 2017
No notice
799.
Li X, et al. Changes in the microbial communities in vacuum-packaged smoked bacon during storage. Food Microbiol. 2019;77:26-37.
Not in our library10.1016/j.fm.2018.08.007
800.
Gootenberg JS, et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6. Science. 2018;360:439-444.
Not in our library10.1126/science.aaq0179
801.
Gootenberg JS, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356:438-442.
Not in our library10.1126/science.aam9321
802.
Sacks D, et al. Multisociety consensus quality improvement revised consensus statement for endovascular therapy of acute ischemic stroke. Int J. Stroke. 2018;13:612-632.
Not in our library10.1177/1747493018778713
803.
Zhang C, et al. An oral polyphenol host-guest nanoparticle for targeted therapy of inflammatory bowel disease. Acta Biomater. 2023;169:422-433.
Not in our library10.1016/j.actbio.2023.08.020
804.
Xu H, et al. Duplex responsive nanoplatform with cascade targeting for atherosclerosis photoacoustic diagnosis and multichannel combination therapy. Adv. Mater. 2023;35:e2300439.
Not in our library10.1002/adma.202300439

Cited by papers we hold 2

Invasion and metastasis in cancer: molecular insights and therapeutic targets · 2025
No notice
Nanotechnology in healthcare, and its safety and environmental risks · 2024
No notice

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.